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GOLPH3 and GOLPH3L are highly conserved proteins found across the 
eukaryotic lineage. Their yeast homolog, Vps74p was shown to interact directly with 
several cis and medial mannnosyltransferases and anchors these enzymes at the Golgi. 
Subsequently, this interaction is critical in determining the outcome of both N and O-
linked glycosylation in yeast. The human GOLPH3 proteins were shown to be able to 
correct for phenotypic defects seen in vps74 deleted yeast cells, thus it is speculated 
that Vps74p and GOLPH3 perform a conserved function at the Golgi. 
To gain further insight into the role of GOLPH3, we screened for novel 
interacting partners of GOLPH3 and its isoform GOLPH3L through the utilization of 
a T7 phage display system. Both proteins were found to bind the stem region of 
human protein O-linked mannose beta-1, 2-N-actetlyglucosaminyltransferase 1 
(POMGnT1), a glycosyltransferase involved in O-mannosylation of α-dystroglycan. 
These interactions were verified in vitro and in addition, the GOLPH3 proteins and 
POMGnT1 were shown to co-localize at the Golgi. Importantly we show that loss of 
this interaction correlated with the inability of POMGnT1 to localize to the Golgi. To 
assess the biological relevance of this novel interaction, we demonstrated that the 
RNAi-mediated knockdown of GOLPH3 and GOLPH3L reduced the functional 
glycosylation of α-dystroglycan, a glycoprotein which constitutes the dystrophin 
glycoprotein complex present in the sarcolemma of muscle fibres. Previous studies 
showed that mutations in POMGnT1 lead to muscle-eye-brain disease (MEB). We 
discovered that three single missense mutations in the stem domain of POMGnT1 
previously described in MEB patients exhibited reduced binding to GOLPH3 and 
failed to display Golgi localization.  
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These findings reveal a novel role for GOLPH3 and GOLPH3L in mediating 
interactions with POMGnT1 and maintaining its Golgi localization. Loss of this 
interaction could underlie one of the molecular mechanisms leading to the 
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CHAPTER 1 INTRODUCTION  
1.1 Background 
The asymmetric distribution of glycosyltransferases at the mammalian Golgi 
facilitates the highly ordered process of glycosylation as it allows for the stepwise 
addition of sugars onto a glycoprotein and thus determines the overall structure of an 
oligosaccaharide (Rothman, 1994). Mislocalization of these enzymes or impairment 
of their function is known to lead to conditions such as congenital disorders of 
glycosylation (Jaeken and Matthijs, 2007) and congenital muscular dystrophy 
(Mendell et al., 2006). However the mechanism of mammalian glycosyltransferase 
localization at the Golgi is not well defined. Their distribution is thought to be 
maintained via a dynamic process which involves the enzymes moving forward 
through the Golgi together with anterograde cargo only to be recycled back to their 
resident compartments via the retrograde transport carriers, coat protein complex 1 
(COP1) vesicles (Allan and Balch, 1999). However, Golgi resident 
glycosyltranferases do not possess COP1 binding motifs and are thus incapable of 
direct interaction with these vesicles. This led to the search for the intermediary 
protein that could promote the incorporation of glycosyltransferases into COP1 
vesicles, resulting in the identification of the yeast Vps74p (Tu et al., 2008 and 
Schmitz et al., 2008).  
Vps74p directly interacts with cis and medial mannosyltransferases as well as 
with several components of the COP1 coat (Schmitz et al., 2008; Tu et al., 2008). 
Vps74p is postulated to act as an adaptor that facilitates mannosyltransferase 
incorporation into retrograde COP1 vesicles and ultimately controls the steady state 
distribution of these enzymes by anchoring them at the yeast Golgi (Schmitz et al., 
2008; Tu et al., 2008). This is evident by the observation that deletion of vps74 leads 
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to the loss of Golgi localization of several mannosyltransferases, subsequently 
resulting in defects in both N-linked and O-linked glycosylation (Schmitz et al., 2008; 
Tu et al., 2008). 
The mammalian homologue of Vps74p, Golgi phosphoprotein 3 (GOLPH3, also 
known as GPP34 and GMx33 in rat) was discovered in proteomic studies to identify 
novel resident proteins of the Golgi (Wu et al., 2000 and Bell et al., 2001). Both 
GOLPH3 and its isoform, Golgi phosphoprotein 3-like (GOLPH3L) do not display 
homology to any known mammalian functional domains or proteins (Wu et al., 2000). 
Nevertheless, GOLPH3 represents a highly conserved protein found across the entire 
eukaryotic lineage (Wu et al, 2000). Importantly, the GOLPH3 proteins were shown 
to be able to correct for phenotypic defects seen in VPS74 deleted yeast cells (Tu et 
al., 2008). Thus it is speculated that Vps74p and GOLPH3 perform a conserved 
function at the Golgi (Wu et al., 2000; Tu et al., 2008). Here, we aim to gain a better 
understanding into the role of GOLPH3 specifically in the context of mammalian 
glycosylation through the identification of novel binding partners.  
1.2 Thesis objectives 
The objectives of this thesis consist of:  
(1) The use of a T7 phage display platform to identify novel binding partners of 
the GOLPH3 proteins and the verification of the novel interaction in an 
independant system. 
(2) To elucidate the physiological significance for the interaction in a biological 
system.  




1.3 Thesis Organization  
This thesis consists of 7 chapters. Chapter 1 offers a brief introduction to 
GOLPH3 and states the objectives of the thesis. Chapter 2 is a literature review 
encompassing an introduction into glycosyltransferase subcompartmentalization at the 
Golgi followed by the examination of the role that Vps74p plays in this specific area. 
It also includes an in depth analysis on GOLPH3 which is central to this thesis. The 
role of α-dystroglycan and the impact of glycosylation on its function is then 
explored. The literature review concludes with a description of how mutations in 
POMGnT1 lead to the development of Muscle Eye Brain disease. Chapter 3 provides 
details on the materials and methods used in this thesis. Chapter 4 presents data 
obtained from the T7 phage display screening platform leading to the identification of 
POMGnT1 as a novel GOLPH3 interacting partner. Chapter 5 validates the 
interaction identified in the phage display by assessing for physical protein 
interactions and co-localization of GOLPH3 and POMGnT1. The role of GOLPH3 in 
maintaining the Golgi localization of POMGnT1 is also examined in this chapter. 
Chapter 6 assesses the impact of knockdown of GOLPH3 on the glycosylation of α-
dystroglycan and attempts to investigate the potential clinical significance for this 
study by examining the localization of POMGnT1 mutants present in MEB patients as 
well as its interaction with GOLPH3. Chapter 7 summarizes the main conclusions 







CHAPTER 2 LITERATURE REVIEW 
2.1  Structure of the Golgi 
2.1.1   Golgi subcompartmentalization  
             A major role of the Golgi apparatus is to serve as the site for extensive 
carbohydrate chain elongations and elaborations of newly synthesized proteins. The 
Golgi has a unique morphology as it is essentially a collection of flattened membrane 
enclosed compartments called cisternae that is stacked in a directional manner. 
Following initial glycosylation in the ER, proteins are folded and transported to the 
cis Golgi network (CGN) which is an extension of the ER membrane. The proteins 
then undergo an ordered series of modification as it moves through the first Golgi 
processing compartment; the cis cisternae followed by the medial and trans cisternae 
where glycosylation is then completed. At the trans Golgi network (TGN), the 
modified proteins are then selectively transported within vesicles to various 
organelles. Each Golgi cisternae consists of a specific set of resident proteins. This 
family of type II membrane proteins, the glycosyltransferases, are required for the 
postranslational modification of proteins and are thus responsible for the synthesis of 
the vast diversity of complex oligosaccharides that are commonly observed on 
glycoproteins. The positioning of glycosyltransferases at successive compartments of 
the Golgi generally reflects the order in which these enzymes function, thus early 
acting enzymes are enriched in the early cisternae (cis) while the later acting enzymes 
are enriched in the late cisternae (trans) (Farquhar, 1985 and Dunphy and Rothman, 
1985). Other studies suggest that the localization of enzymes within a specific 
subcompartment is not as precisely defined but instead form overlapping 
concentration gradients across the Golgi (Glick et al., 1997). 
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2.1.2   The significance of Golgi subcompartmentalization 
The glycosylation pathway is a highly ordered process where each step is 
reliant on the successful completion of the previous step (Puthenveedu and Linstedt, 
2005). The asymmetric distribution of resident proteins across the Golgi stack 
facilitates this process as it permits proteins to be exposed to enzymes sequentially 
and subsequently allows glycan modification to occur consecutively. The 
subcompartmentalization of glycosyltransferases ultimately dictates the structure of 
glycans formed in vivo (Rothman, 1994). One study showed that upon redistribution 
of Golgi enzymes to the ER, the enzymes remain active however glycosylation is 
severely affected (Karhinen L and Makarowm, 2004). This observation can be 
attributed to the abolishment of sequential enzyme exposure (Karhinen L and 
Makarowm, 2004). An additional factor that could account for the impairment of 
glycosylation could be due to the dilution in concentrations of the Golgi enzymes 
upon redistribution to the vast ER membranes (Karhinen L and Makarowm, 2004). 
Thus, subcompartmentalization of enzymes within the Golgi stack may allow for the 
concentration of specific enzymes within cisternae which may be required for 
efficient enzyme activity (Puthenveedu and Linstedt, 2005). Subcompartmentalization 
may also permit the establishment of a pH, lipid and ionic gradient across the Golgi 
stack, thus creating distinct lumenal environment that is optimized for specific Golgi 
enzymes (Puthenveedu and Linstedt, 2005). Studies have shown that a pH gradient 
can facilitate conformational changes in resident proteins (Fullekrug and Nilsson, 
1998). One direct consequence of this is the enhancement of COP1 recruitment by 
these resident proteins (Fullekrug and Nilsson, 1998).  
Taken together, subcompartmentalization plays a critical role at the Golgi as it 
provides optimal conditions for effective glycan processing (Puthenveedu and 
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Linstedt, 2005). Defects in function or localization of glycosyltransferases are known 
to severely impact human conditions. Depending on the specific glycosylation 
pathway that is affected, defects in these enzymes leads to conditions known as 
congenital disorders of glycosylation (CDG) (Jaeken and Matthijs, 2007) or 
congenital muscular dystrophy (CMD) (Mendell et al., 2006).   
2.1.3  Mechanisms of Golgi subcompartmentalization  
Two models have been established to account for movement of Golgi enzymes 
within the Golgi stack. The first is the vesicular transport model which describes the 
Golgi cisternae as stable entities where proteins are selectively transported within 
anterograde vesicles to specific cisternae while resident proteins are excluded from 
these vesicles and are thus retained (Rothman, 1994). Alternatively, the cisternal 
maturation model suggests that the Golgi constantly matures and moves forward, 
resulting in passive movement of cargo move through the Golgi stack (Morre, 1987). 
Resident proteins are thought to be recycled via retrograde transport carriers, COP1 
(Allan and Balch, 1999). It is thought that the two mechanisms are not mutually 
exclusive but rather, function simultaneously (Pelham et al., 2000; Orci et al., 1997; 
Orci et al., 2000).  The generation and maintenance of the asymmetric distribution of 
resident proteins across the Golgi stack is thus a consequence of both anterograde and 














Figure 1.1 Two models to account for protein transport through the Golgi           
(Opat et al., 2001) 
 In the vesicular transport model, cargo is transported within 
anterograde vesicles which bud and fuse from static cisternae while 
resident proteins are excluded from these vesicles. In the cisternal 
maturation model, cargo molecules move through the Golgi stack 
passively as the cisternae moves forward while resident proteins are 
recycled by retrograde transport.  
Additional mechanisms however must be involved in maintaining this distribution. 
One school of thought is that various Golgi enzymes compete for a limited number of 
sites in COP1 vesicles. A computer simulation generated by Glick et al predicts that 
the strongest enzyme competitors will be enriched in cis cisternae while enzymes with 
intermediate and weaker abilities will be enriched in the medial and trans cisternae 
respectively. This competitiveness is thought to be dependent upon the binding 
affinities of transmembrane sequences of Golgi enzymes to receptors on COP1 
vesicles (Bretscher and Munro, 1993). Alternatively, specific Golgi enzymes are 
selectively recruited into COP1 vesicles via a lipid sorting mechanism based on the 
thickness of the vesicle membrane (Munro, 1998). To improve the robustness of the 
competition model, Weiss and Nilsson have suggested that the lumenal milieu of the 
cisternae also plays a role in determining the position of enzyme residency. In this 
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model, the authors postulate that resident Golgi proteins exist in either a resting or 
sorting state depending on the lumenal environment of the cisternae. As the cisternae 
matures in a cis to trans fashion, the lumenal environment changes accordingly in 
terms of its pH and lipid composition resulting a resident protein being switched to a 
sorting state. Subsequently these enzymes are incorporated into retrograde transport 
carriers, which transport the proteins back to earlier cisternae of a different lumenal 
milieu. This results in a protein switching back to a resident state. The cycle is 
repeated as the cisternae continue to mature.  
2.1.4  Grey area in Golgi subcompartmentalization  
A central event pertaining to the models described above is the incorporation 
of Golgi enzymes into the retrograde COP1 vesicles. Sorting signals present on 
cytoplasmic domains of Golgi resident proteins are thought to be important in 
facilitating their incorporation into COP1. Indeed one such signal,  K(X)KXX has 
been shown to bind directly with COP1 (Cosson and Letourneur, 1994 and 
Letourneur et al., 1994) This sequence however, is restricted to proteins that reside in 
the early parts of the glycosylation pathway, specifically in the ER and ER  to Golgi 
interface (Cosson and Letourneur, 1994 and Letourneur et al., 1994). Other Golgi 
resident glycosyltransferases do not possess COP1 binding motifs and are thus 
incapable of direct interaction with these retrograde transport carriers (Tu et al., 
2008). Subsequent studies to identify proteins that could as an intermediate by 
binding directly to Golgi enzymes and subsequently promote their incorporation of 
glycosyltransferases into COP1 vesicles, led to the identification of the yeast Vps74p 




2.2   Yeast Vps74p 
2.2.1   Identification of Vps74p 
The yeast protein Vps74p was identified in two independent studies in yeast. 
In the first study, a genetic screen was performed to identify genes that could suppress 
the lethal phenotype associated with the deletion of Sft1p (Banfield, 1995). Sft1p 
represents an essential Golgi resident SNARE (soluble N-ethylmaleimide-sensitive 
factor attachment protein receptor) and is known to play a role specifically in 
retrograde traffic within the yeast Golgi. The subsequent study also involved a genetic 
screen aimed at identifying genes essential in the absence of a RabGTPase Ypt6p 
(Tong et al., 2004). Ypt6p has been proposed to function in the retrograde pathway 
from endosomes to the TGN based on observations that  Ypt6p null mutants causes 
the partial mis-sorting of the vacuolar protease, carboxypeptidase Y (CPY) and 
mislocalization of the TGN proteins to the vacuole (Tsukada and Gallwitz, 1996; 
Tsukada et al., 1999).  The function of the yeast Vps74p was later investigated and its 
primary roles are summarized in chapters 2.2.2 and 2.2.3.  
2.2.2   Vps74p required for localization of yeast mannosyltransferases 
The localization of several GFP tagged Golgi mannosyltransferases were 
assessed in wild type yeast cells and vps74 deleted cells (vps74). The 
mannsoyltransferases assessed represented key enzymes that are responsible for 
catalyzing the initial steps in N and O-linked glycosylation in yeast. The N-linked 
mannsoyltransferases included Och1p (see Figure 1.2), which transfers the initial 
mannose residue to the core oligosaccharide (Nakayama et al., 1992), Mnn9p which 
catalyses further elongation after Och1p by generating an unbranched α1, 6 mannan 
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chain (Jungmann and Munro, 1998) as well as Mnn2p and Mnn5p which initiates 








Figure 1.2 Structure of N-linked oligosaccharide in yeast (Hamilton and 
Gerngross, 2007) 
Och1p, Mnn9p, Mnn2p and Mnn5p are involved in the extension of the 
core oligosachharide with mannose residues.  
 
The O-linked α1, 2-mannosyltransferase Kre2p (also known as Mnt1p) (Figure 1.3), 
represents a key enzyme responsible for elongation of O-linked glycans as it is 















Figure 1.3 Structure of O-linked oligosaccharides in yeast (Strahl-Bolsinger et 
al., 1999) 
Pmtp, Mnt1p, Ktr1p, Ktr3p and Mnn1p are mannosyltransferases 
participating in the synthesis of yeast O-linked glycans.  
 
In wild type cells, these proteins exhibited a punctate like pattern which is 
characteristic of a Golgi distribution. However in the vps74 strain, the proteins were 
mislocalized either to a vesicle like haze or the lumen of the vacuoles (Tu et al., 
2008). The above mentioned mannosyltransferases reside in the cis and medial 
compartments of the yeast Golgi and represented the only group of proteins that were 
affected by the depletion of Vps74p. The localization of other Golgi proteins which 
included the membrane spanning proteins (GFP-Rer1p, Sys1p-GFP and Tvp-15p-
GFP), the TGN proteins (Kex2p-GFP and GFP-Ste13p) and peripheral Golgi 
membrane proteins (Arf1p, Cop1p and Sec7p) were unaffected by the deletion of 
VPS74 (Schmitz et al., 2008). The N-terminal tails of the cis and medial 
mannosyltransferases were predicted to mediate their interaction with Vps74p as the 
latter is thought to be a peripheral membrane protein and would thus exist on the 
cytosolic side of the Golgi. Indeed Schmitz et al showed that Vps74p is able to 
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interact with the first 15 amino acids (N-terminus) of these mannosyltransferases by 
performing GST pull down assays. When key amino acids within the N-terminal tails 
of the Kre2p was substituted, the protein lost its interaction with Vps74p as well as its 
ability to localize to the Golgi which further supports the notion that that it is the 
cytoplasmic tails of mannosyltransferases that interact with Vps74p (Tu et al., 2008). 
In addition to binding to mannosyltransferases, Vps74p was also shown to interact 
with subunits of COP1 (Ret2p and Sec26p) in in vitro assays (Tu et al., 2008). 
Schmitz et al was not able to demonstrate this interaction between Vps74p and COP1 
subunits however according to their unpublished data, mutations in COP1 subunit led 
to the partial mislocalization of Kre2p which is similar to the phenotype seen in the 
vps74 strain.  
2.2.3   Vps74p required for proper N and O-linked glycosylation in yeast 
The critical role of Vps74p in localizing mannosyltransferases at the yeast 
Golgi is highly indicative that the protein plays a role in glycosylation as well. Indeed 
Vps74p was shown to be required for both N and O-linked glycosylation in yeast (Tu 
et al., 2008, Schmitz et al., 2008). A model protein glycosyl-phosphatidylinositol 
(GPI) anchored protein (Gas1p), which is known to be modified by both N and O-
linked glycans as it traverses through the Golgi to the cell surface, was shown to be 
negatively affected by the deletion of VPS74 (vps74) (Tu et al., 2008). In the 
deleted strain, the mature form of Gas1p migrated faster than that of the wild type 
strain which is suggestive of a reduction in glycosylation (Tu et al., 2008). Analysis 
of Gas1p localization of through the use of a red fluorescent tag demonstrated a 
typical cell surface distribution suggesting that the transport of Gas1p is unaffected by 
deletion of VPS74 (Tu et al., 2008). The authors then went on to utilize other model 
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proteins to demonstrate the negative impact of Vps74p on glycosylation. CPY, a 
protein modified by only short core-type N-linked sugars was immunoprecipitated 
from wild type and vps74 strains (Schmitz et al., 2008). The mature form of CPY 
migrated faster in the vps74 strains compared to the WT (Schmitz et al., 2008). In 
contrast the unprocessed core oligosaccharide form of CPY which is added in the ER 
was unaffected by the deletion of VPS74 (Schmitz et al., 2008). This result clearly 
demonstrated that the vps74 strain harboured defects in the processing of N-linked 
glycans. Heat shock protein 150 (HSP150) which is an extensively O-glycosylated 
protein was exogenously expressed in wild type and vps74 cells and precipitated. 
HSP150 was observed as a single band of 150kDa in wild type cells however 
displayed several shorter bands in vps74cells, with the largest band migrating below 
150kDa (Schmitz et al., 2008). Thus Vps74p is required for proper glycosylation of 
O-linked glycoproteins as well (Schmitz et al., 2008).  
2.3   The Vps74p mammalian homolog, GOLPH3 
2.3.1   Identification of GOLPH3 
The rat homologue of Vps74p, Gmx33 was identified in a proteomics 
approach that set out to identify novel proteins that are residents of the Golgi (Wu et 
al., 2000). Two isoforms of Gmx33 exists, represented by α and  . The human 
orthologues of Gmx33α and Gmx33β (GPP34 and GPP34R) were subsequently 
identified in a similar proteomic analysis (Bell et al., 2001). In this study, purified 
hepatic Golgi apparatus was biochemically separated using Triton X-114 and 
subjected to mass spectrometric analysis. This led to the identification of the novel 
protein Golgi phosphoprotein 3 (GPP34) and Golgi phosphoprotein 3-like (GPP34R), 
also known as (GOLPH3 and GOLPH3L respectively). The GOLPH3 represents a 
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highly conserved protein found across the eukaryotic lineage from yeast to mammals 
(see Figure 1.4). It was thus speculated that the role of GOLPH3 at the mammalian 
Golgi could be similar to its yeast counterpart, Vps74p (Wu et al., 2000). Indeed it 
has been shown that GOLPH3 and GOLPH3L are able to partially correct for the 














Figure 1.4 Protein alignment of Gmx33α and the identified homologs                         
(Wu et al, 2000) 
  Consensus sequences are shaded grey. Potential phosphorylation sites 
are labelled as solid colored lines and potential myristylation sites are 
labelled as hatched colored lines  
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2.3.2   Properties of GOLPH3 
2.3.2.1 Localization of GOLPH3 
GOLPH3 represents a unique protein as it does not display homology to any 
known mammalian functional domains or proteins (Wu et al., 2000). Northern blot 
analysis of the rat homologue of GOLPH3, Gmx33 demonstrated that the Gmx33 
mRNA is ubiquitously expressed as it was detected in all tissues tested (heart, brain, 
spleen, lung, liver, skeletal muscle, kidney and testis) (Wu et al., 2000). 
Immunofluorescence studies of Gmx33, has revealed that the protein predominantly 
localizes to the Golgi, specifically the trans Golgi, although a cytosolic pool of 
Gmx33 was also identified (Wu et al., 2000; Snyder et al., 2006). Fluorescence 
recovery after photobleaching (FRAP) analysis showed that, Gmx33 cycles rapidly 
between the membrane and cytosolic pools (Snyder et al., 2006).  
As transmembrane domains or signal sequences have not been identified for 
GOLPH3, its Golgi localization is speculated to be mediated by interactions with 
Golgi membrane proteins (Wu et al., 2000; Roy and Levine, 2004). To further support 
this notion, a significant proportion of Gmx33 (55%) preferentially partitions into the 
detergent soluble phase following Triton-X114 treatment which is suggestive of the 
fact that Gmx33 interacts with a membrane component (Wu et al., 2000). It is 
important to note that Gmx33 was predicted to be a cytosolic protein based on its 
primary sequence (Wu et al., 2000). Interestingly, Gmx33 was also present in the 
detergent insoluble phase within high molecular weight complexes (Wu et al., 2000). 
As the molecular weight of these complexes does not correspond to that of Gmx33 
multimers, this result suggests that Gmx33 may forms complexes with several binding 
partners (Wu et al., 2000). Identification of these binding partners will be key to 
elucidating the function of GOLPH3 at the mammalian Golgi.  
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2.3.2.2 Post-translational modifications on GOLPH3 
Analysis of the primary sequence of the rat GMx33 revealed the presence of 
several potential phosphorylation sites (labeled as solid coloured lines in Figure 1.4) 
(Wu et al., 2000). Two-dimensional (2D) immunoblot analysis of Gmx33 showed that 
the protein was composed of at least eight spots of varying isoelectric points (5.4-6.1) 
compared to the single band observed by one-dimensional (1D) immunoblot analysis, 
which indicates the existence of several forms of Gmx33 (Wu et al., 2000). Pre-
treatment with alkaline phosphatase resulted in the disappearance of the majority of 
the bands, confirming the speculation that several of the Gmx33 forms are indeed 
phosphorylated (Wu et al., 2000). However, phosphorylation is thought to be 
restricted to the membrane bound form of Gmx33 and not the cytosolic form (Snyder 
et al., 2006).  The association of Gmx33 with the Golgi was shown to be dependent 
on the presence of ATP and/or the GTP analogue GTPỵS, a process that is likely to 
involve phosphorylation (Snyder et al., 2006).   
Three out of the eight spots observed on the 2D immunoblot was not affected 
by alkaline phosphatase pre-treatment suggesting the presence of other post-
translational modifications (Wu et al., 2000). Wu et al identified several N-
myristylation sites on the Gmx33 primary sequence (labelled as hatched lines in 
Figure X) which could thus account for the additional post-translational modification 
present on this protein.  
2.3.3   Known roles of GOLPH3 in mammalian system 
As described above, Gmx33 associates with the trans-Golgi matrix in an ATP 
and or GTP/dependent manner and is thus predicted to be a Golgi matrix protein of 
which the latter, primarily functions to maintain the structure of the Golgi. However 
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Snyder et al demonstrated that depletion of Gmx33 does not result in major changes 
in Golgi structure and subsequently defines Gmx33 as an ‘atypical’ Golgi matrix 
protein. Through the use of live- cell imaging, fluorescently labelled Gmx33 was 
shown to segregate into puncta along the length of tubules that emerged from the 
Golgi and in addition was shown to localize to the endosome and plasma membrane 
(Snyder et al., 2006). Taken together, these observations suggest that Gmx33 could be 
implicated in sorting processes from the Golgi (Snyder et al., 2006). A subsequent 
study has shown that GOLPH3 binds to phophatidylinositol-4-phosphate (PtdIns4P) 
on Golgi membranes as well as to myosin18A (MYO18A) which thereby links the 
Golgi membrane to the actin cystoskeleton (Dippold et al., 2009). It was suggested 
that the PtdIns(4)P-GOLPH3-myosin18A linkage generates a tensile force that is 
responsible for efficient trafficking of proteins from the Golgi to the plasma 
membrane (Dippold et al., 2009). To substantiate this, they showed that the 
knockdown of GOLPH3 resulted in the dilation of the Golgi cisternae specifically at 
the trans face and in turn impaired the anterograde trafficking of a fluorescently 
labelled Vesicular Stomatitis Virus Glycoprotein (VSVG) to the plasma membrane. 
The knockdown of GOLPH3 was also shown to reduce the number of vesicles and 
tubules leaving the Golgi and thus may implicate GOLPH3 in efficient exit from the 
Golgi (Dippold et al., 2009). The change in structure of the Golgi following GOLPH3 
knockdown is in contrast to earlier investigations which clearly demonstrated that the 
knockdown of this protein does not disrupt the structure of the Golgi in any 
significant way (Snyder et al., 2006).  
Although these results has implicated GOLPH3 is trafficking and vesicle 
formation, its role in glycosylation is still unknown. Representative 
glycoysltransferases involved in N-linked glycosylation (α-mannosytransferase II, β-
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1,4-galactosytransferase and α-2,6-sialytransferase) failed to demonstrate binding to 
GOLPH3 (Dippold et al., 2009). In addition, the knockdown of GOLPH3 did not 
affect the Golgi localization of these transferases (Dippold et al., 2009).  Dippold et al 
suggests that the role of the yeast GOLPH3 (Vps74p) in maintaining the steady state 
distribution of glycoysltransferases at the yeast Golgi, is not conserved in mammals 
and thus represents a species difference. However, a recent study has revealed an 
interaction between GOLPH3 and a mammalian glycosyltransferase, specifically the 
Core 2 N-acetlyglucosaminyltransferase 1 (C2GnT1), an enzyme implicated in the 





al., 2012).  This glycan is a selectin ligand that is known to be involved in leukocyte 
trafficking (McEver and Cummings, 1997., Li et al., 1996). The knockdown of 
GOLPH3 resulted in the mislocalization of C2GnT1 to the endosplasmic reticulum 
with subsequent reduced synthesis of the C2-O-sLe
X
 glycan (Ali et al., 2012). This 
study ultimately linked GOLPH3 to cell tethering, rolling and adhesion (Ali et al., 
2012).  
Currently, there is only one study which investigated the role of GOLPH3L in 
a mammalian system. In this study, the expression pattern of GOLPH3L was shown 
to be restricted to a subset of of cell types and tissues, specifically secretory tissues 
(Ng et al., 2013). This is in contrast to GOLPH3 which is ubiquitously expressed in 
all cell types and tissues (Ng et al., 2013). Similar to GOLPH3, the knockdown of 
GOLPH3L was shown to be unable to affect the Golgi localization of several 
glycosyltransferases involved in N-linked glycosylation (Ng et al., 2013). However, 
GOLPH3L differs from GOLPH3 in that the former is unable to interact with 
MYO18A (Ng et al., 2013). As a consequence, perturbations of GOLPH3L 
expression levels produces effects on the Golgi morphology that is the exact opposite 
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to that when GOLPH3 expression levels are perturbed (Ng et al., 2013). Thus 
GOLPH3L is speculated to antagonize GOLPH3 in regulating the morphology of the 
Golgi (Ng et al., 2013).  
2.3.4   Identification of a novel GOLPH3 variant  
Recent work on the GOLPH3 protein has led to the identification of an 
alternatively spliced mouse Gmx33α variant, Gmx33αV (Nagano-Ito et al., 2007). In 
this variant, the second and third exons that is usually present in the full length protein 
is deleted causing a frameshift mutation which generates a stop codon in the fourth 
exon. The resultant splice variant mRNA encodes a short peptide of only 81 amino 
acids. Similar to the full length Gmx33α, the intracellular distribution of the variant 
form was defined at the Golgi (Nagano-Ito et al., 2007). However, significant 
differences were observed in the tissue distribution of the two proteins. Real-time 
PCR (RT-PCR) analyses demonstrated that Gmx33α mRNA levels were similar in all 
tissues tested (brain, liver, kidney, heart, skeletal muscle and testis). Interestingly, 
mRNA expression of Gmx33αV was shown to be highly expressed specifically in the 
skeletal muscle (Nagano-Ito et al., 2007).  The presence of the alternatively spliced 
Gmx33α variant in this tissue is highly suggestive of the fact that the protein plays an 
important biological role in this tissue of which its function remains to be identified. 
Importantly, the variant form was also identified in human HeLa cells (Nagano-Ito et 
al., 2007) and is thus significantly relevant to our work.  
2.3.5   Effects of GOLPH3 depletion  
The deletion of the yeast GOLPH3 (Vps74p) did not result in obvious effects 
on yeast cell growth (Tu et al., 2008). In contrast, gene knockout of GOLPH3 is 
Drosophila melanogaster results in embryonic lethality. Consequently an animal 
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model for GOLPH3 does not exist which hampers efforts to identify the role of this 
protein. An alternative approach to elucidating the function of GOLPH3 at the Golgi 
is to identify its binding partners. Using a T7 phage display system as a large scale 
screening platform, we have screened for novel interacting partners of GOLPH3. This 
led to the identification of a previously unknown interaction of GOLPH3 with human 
protein O-linked mannose beta-1,2-N-actetlyglucosaminyltransferase 1 (POMGnT1) 
which is involved in a unique type of mammalian glycosylation, O-mannosylation.  
2.4   O-mannosylation of α-dystroglycan 
2.4.1  O-mannosylation in mammalian systems 
O-mannosylation is commonly known as a yeast type modification (Nakajima-
Ballou, 1974; Raizada et al., 1975; Hayette et al., 1992). Glycoproteins modified by 
this pathway predominantly reside in the yeast cell wall and are vital for cell viability, 
morphology and cell wall integrity (Strahl-Bolsinger et al., 1999). O-mannosylation 
in mammalian cells is not as ubiquitous but is restricted to a limited group of 
glycoproteins, specifically those of the brain, nerve and skeletal muscle. The core O-
mannosyl glycan found in these tissues is the tetrasaccharide NeuAcα2-3Galβ1-
4GlcNAcβ1-2Man-Ser/Thr (see Figure 1.5, i). The addition of the initial mannose 
onto Serine/Threonine residues of proteins is mediated by an ER restricted enzyme 
complex consisting of protein O-mannosyltransferase 1 (POMT1) and 2 (POMT2) 
(Jurado et al., 1999; Willer et al., 2002; Manya et al., 2004). POMT1 displays 
significant homology to the yeast protein O-mannosyltransferase (PMTs) which is 
also known to mediate the similar attachment of mannose onto Serine/Threonine 
residues of specific yeast proteins (Strahl-Bolsinger et al., 1999). The addition of the 
subsequent sugars occurs in the Golgi apparatus. Protein O-linked mannose β2-N-
acetylglucosaminyltransferase 1 (POMGnT1) catalyses the second step in the O-
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mannosylation pathway by mediating the transfer of N-actetylglucosamine (GlcNAc) 
from UDP-GlcNAc onto the mannose in the 2-OH position (Yoshida et al., 2001; 
Zhang et al., 2002). The GlcNacβ1-2Man linkage catalyzed by POMGnT1 is known 
to be unique to mammals as POMGnT1 does not demonstrate homology to enzymes 
in any other genome (Yoshida et al., 2001). A recent glycomic analysis in a 
POMGnT1 null mouse model demonstrated a clear absence of classically extended O-
mannosyl glycans, suggesting that no compensatory glycosyltransferases exists for 
POMGnT1 (Stalnaker et al., 2011). This result highlights the critical role of 
POMGnT1 in the O-mannosylation pathway. Further elongation of the O-mannose 
glycan is thought to be mediated by members of the β1,4- galactosyltranferase, 
(Amado et al., 1999) and the α2,6-sialyltransferase (Tsuji, 1996) families.  
The structures of the other O-mannosyl glycans found in mammals represent 
variations of tetrasaccharide NeuAcα2-3Galβ1-4GlcNAcβ1-2Man-Ser/Thr. One such 
structure is the O-mannosyl-linked Lewis-X antigen Gal β1,4(Fucα1,3) 
GlcNAcβ1,2Manα-O (ii in Figure 1.5) which was identified in sheep brain (Chiba et 
al., 1997). Studies suggest this glycan structure is not present in skeletal muscle due 
to the lack of interaction with fucose binding lectins (Scott et al., 1988). A branched 
structure containing a 2,6-di-substituted mannose (iii in Figure 1.5) was identified in 
the brain. Generation of this structure in the brain has been attributed to the presence 
of GnTV-β which is specifically expressed in this organ (Chai et al., 1999; Inamori et 
al., 2004). Another unique structure is the HNK-1 epitope in which sialic acid is 
replaced with sulfoglucuronic acid (Figure 1.5, iv). Again through the use of lectin 
binding, this structure was only shown to be present on the O-mannosylated protein α-










Figure 1.5 Schematic representation of O-mannosyl glycans present in 
mammals (Willer et al., 2003) 
The core Galβ1-4GlcNAcβ1-2Man-Ser/Thr structure (highlighted in 
yellow) is common to all mammalian O-mannosyl glycans. α-
dystroglycan contains the siaylated core O-mannose structures (i) and 
the O-mannosyl Lewis X structures (ii). Branched structures (iii) and 
O-mannosyl-linked HNK-1 epitopes (iv) were identified in brain.  
2.4.2  Substrates of the O-mannosylation pathway   
2.4.2.1  α-dystroglycan and the importance of glycosylation for its function 
The most well characterized protein modified by the O-mannosylation 
pathway is α-dystroglycan. α-dystroglycan is encoded on the same gene (DAG1) as β-
dystrogylycan. The two proteins are post-translationally cleaved but remain tightly 
associated via non-covalent interactions and both represent central components of the 
dystrophin glycoprotein complex (DGC). The DGC, which exists as a multimeric 
protein complex found in the sarcolemmma membrane surrounding muscle fibres, 
represents the major structural support system for the sarcolemma during muscle 
contraction and is thought to mechanically protect the sarcolemma against stresses 
and injury during muscle contraction (Petrof et al., 1993). The DGC acts by 
physically coupling the extracellular matrix that surrounds each myofibre to the 
intracellular actin cytoskeleton (Blake et al., 2002; Henry and Campbell, 1999; 
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Durbeej et al., 1998). α-dystroglycan which resides on  the outer surface of the 
sarcolemma, interacts with several ligands present in the extracellular matrix which 
includes agrin, perlecan, neurexin and most importantly laminin (Bowe et al, 1994; 
Campanelli et al., 1994; Gee et al., 1994 and Sugiyama et al., 1994). A representation 
of α-dystroglycan within the DGC is shown in Figure 1.6 
Each of the ligands in the ECM posseses laminin G (LG)-like domain which is 
responsible for binding to α-dystroglycan in a Ca2+ dependant fashion (Hohenester et 
al., 1999; Tisi et al., 2000). A key feature that is essential for establishing an 
interaction between α-dystroglycan and its ligands is the proper glycosylation of α-
dystroglycan glycoprotein (Michele et al., 2002; Michele and Campbell, 2003 and 
Muntoni et al., 2004). The transmembrane protein, β-dystroglycan spans the 
sarcolemma membrane and interacts extracellularly with α-dystroglycan and 
intracellularly with dystrophin which in turn binds to the actin cytoskeleton (Ervasti 
and Campbell, 1991). Other proteins within the core skeletal muscle DGC include the 
sarcoglycans (Ervasti and Campbell, 1991), sarcospan (Crosbie et al., 1997), 

















Figure 1.6 Schematic representation of DGC within the skeletal muscle 
(Barresi and Campbell, 2005) 
 The DGC links the extracellular matrix outside the cell with the actin 
cytoskeleton inside the cell. Dark circles on α-dystroglycan indicate O-
linked sugar chains. Branches indicate N-linked sugar chains.  
 
It has been shown that a group of human muscular disorders called 
dystroglycanopathies stem from the hypoglycosylation of α-dystroglycan (Muntoni et 
al., 2004). This results in the disruption of the vital interaction between α-
dystroglycan and its ligands within the extracellular matrix which ultimately leads to 
muscular dystrophy (Holzfeind et al., 2002; Michele et al., 2002; Kanagawa et al., 
2005). This family of disorders further strengthens the notion that glycosylation of α-
dystroglycan is central to the establishment and maintenance of skeletal muscle 
integrity. The dystroglycanopathies will be discussed in detail in chapter 2.6.4.  
Dystroglycan has also been implicated in the development and maintenance of 
epithelial tissue architecture (Durbeej et al., 1995; Durbeej et al., 1999). Dystroglycan 
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mediates the interaction between epithelial cells and the underlying basement 
membrane by binding to its natural extracellular matrix (ECM) ligand, laminin-111 
(Durbeej et al., 1995; Durbeej et al., 1999). Studies on epithelial derived cancers have 
identified a link between loss of α-dystroglycan glycosylation and cancer progression 
(Muschler, 2002; Sgambato, 2006). Thus dystroglycan glycosylation may serve as a 
mechanism that epithelial derived tumors exploit to alter their adhesion to the ECM 
which subsequently determines their invasive and metastatic potential (Beltran-Valero 
de Bernabe, 2009). The role of α-dystroglycan is not only restricted to laminin 
binding but has also been shown to serve as a cellular receptor for specific viruses 
such as lymphocytic choriomeningtis virus (LCMV) and Lassa fever virus (LFV) 
(Cao et al., 1998; Kunz et al., 2001) as well as the bacteria Mycobacterium leprae (M 
leprae) (Rambukkana et al, 1997; Rambukkana et al, 1998). Recently it was shown 
that LCMV viral recognition and infection of target cells is highly dependent on the 
O-mannosyl initiated glycan structure of α-dystroglycan (Imperiali et al., 2005). The 
glycosylation status of α-dystroglycan also plays an important role in M leprae 
binding as removal of sialic acids on α-dystroglycan abrogates this interaction 
(Rambukkana et al., 1998). This thesis however, will focus on the interaction between 
α-dystroglycan and laminin present in the ECM of skeletal muscle fibres.  
2.4.2.2  Other substrates of the O-mannosylation pathway 
It has been estimated that 30% of the O-linked glycans in the brain is 
represented by O-mannosylated glycans (Chai et al., 1999). Although α-dystroglycan 
represents a prominent glycoprotein of the brain, a recent glycomic analysis in a 
conditional neural knockout of α-dystroglycan mouse model demonstrated that the 
profile of O-mannose initiated glycans was similar to that produced in a wild type 
mouse (Stalnaker et al., 2011). This is highly suggestive that other proteins in the 
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brain are modified by the O-mannosylation pathway, (Stalnaker et al., 2011). 
Receptor protein tyrosine phosphatase ζ (RPTPζ) and its secreted variant phosphacan 
were recently identified as substrates for O-mannosyl glycosylation (Dwyer et al., 
2012). Disruption of the O-mannosyl pathway resulted in the loss of the HNK-1 
epitope (Dwyer et al., 2012); a carbohydrate structure that has previously been 
described on RPTPζ/phosphacan (Maeda et al., 1994). The glycoprotein is primarily 
expressed in the central nervous system (CNS) (Shitara et al., 1994; Maeda et al., 
1995) and is known to play vital roles in key developmental neural processes (Ida et 
al., 1996; Soh et al., 2007). Another glycoprotein known to be modified by the O-
mannosylation pathway is J1/tenascin (Wing et al., 1992). J1/tenascin is known to be 
constituents of the L2/HNK-1 family of neural cell adhesion molecules (Kruse et al., 
1984 and 1985). It is an ECM protein of the nervous system and is involved in 
neuron-astrocyte adhesion (Wing et al., 1992). However, only partial structural 
information is available for this protein (Kruse et al., 1985). This review will thus 
focus on α-dystroglycan as it is the best characterized glycoprotein modified by the O-
mannosylation pathway.  
2.4.3   Glycosylation of α-dystroglycan 
2.4.3.1 Known glycans present on α-dystroglycan 
α-dystroglycan has a predicted molecular weight of 72kDa, however on an 
SDS-PAGE, the protein  reflects an apparent mass of 120-190kDa depending on the 
tissue it was isolated from (156kDa in skeletal muscle, 140kDa in cardiac muscle and 
120kDa in brain and peripheral nerve) (Ervasti et al., 1993). The high molecular 
weight of α-dystroglycan is thought to be a consequence of extensive glycosylation 
which is regulated in a cell type specific manner (Ibraghimov-Beskrovnaya et al., 
1992; Esapa et al., 2003). α-dystroglycan possesses three N-glycosylation sites and a 
27 
 
central highly O-glycosylated mucin like domain containing approximately 50 
potential O-glycosylation sites (Brancaccio et al., 1995; Brancaccio et al., 1997). The 
treatment of α-dystroglycan with N-glycanase reduces the molecular weight of the 
protein by only 4kDa (Ervasti and Campbell, 1991) and more importantly, does not 
affect ligand binding (Ervasti and Campbell, 1993). In contrast, full chemical 
deglycosylation of α-dystroglycan abolishes its laminin binding activity (Ervasti and 
Campbell, 1993). These results highly suggest that the O-linked glycans mediates the 
interactions between α-dystroglycan and laminin (Ervasti and Campbell, 1993). The 
main O-glycan structures found in the mucin like domain consists of the core-1 type 
structures (Galβ1-3GalNAcα-O-Ser/Thr) and the unique O-mannosyl tetrasaccharide 
NeuAcα2-3Galβ1-4GlcNAcβ1-2Man-Ser/Thr (Chiba et al., 1997; Sasaki et al, 1998; 
Smalheiser et al., 1998). To elucidate the entire glycan profile present on α-
dystroglycan, a recent glycomic analysis was performed on α-dystroglycan isolated 
from rabbit skeletal muscle (Stalnaker et al., 2010). This study led to the identification 























Figure 1.7  Quantification of O-glycans released from α-dystroglycan purified 
from rabbit skeletal muscle (Stalnaker et al., 2010) 
 In total, there are more O-GalNAc initiated structures present on α-
dystroglycan. However, O-Man-initiated structures (shaded in grey) 
represent ~50% of the structures by prevalence. 
 
As can be observed from the Figure 1.7, the O-mannose initiated structures 
constituted the majority (> 50%) of the total O-glycan structures present on α-
dystroglycan with the O-mannosyl tetrasaccharide and its asialylated form 
representing 25.2% and 19.7% respectively. The major O-GalNAc initiated structure 
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was the sialylated core 1 oligosaccharide (SialAα2-3Galβ1-3GalNAcα-O-Ser/Thr) 
which formed 34.1% of the total O-glycan structures. The less dominant structures 
represented variations of the core-1 type structures and the O-mannosyl 
tetrasaccharide. Early studies however has, showed that the treatment of α-
dystroglycan with O-glycanase to remove the core 1 oligosaccharide did not affect it 
laminin binding activity (Ervasti and Campbell, 1993). More recent analysis 
implicates the core 1 type glycans in acetyl-choline receptor clustering on the surface 
of muscle cells by utilizing a mechanism that is distinct from the glycan mediated 
binding of α-dystroglycan to laminin (McDearmon et al., 2003). This could account 
for the wide variety of core 1 type O-glcyans found in purified skeletal muscle  
2.4.3.2  Key laminin binding glycans  
The O-mannosyl tetrasaccharide (NeuAcα2-3Galβ1-4GlcNAcβ1-2Man-
Ser/Thr) was previously shown to be required for the interaction of α-dystroglycan 
with laminin (Chiba et al., 1997). However a more recent study conflicts with the 
work performed by Chiba et al as they report that the enzymatic removal of the 
tetrasccharide using a cocktail of endoglycosidases and exoglycosidases 
(Arthrobacter ureafaciens sialidase, β(1-4) galactosidase and β-N-
acetylglucosaminidase) resulted in enhanced binding of α-dystroglycan to laminin, 
and the glycoyslation specific antibodies IIH6 and VIA41 (Combs and Ervasti, 2005). 
The authors further claim that the O-mannosyl tetrasaccharide normally represses the 
binding of laminin and carbohydrate specific antibodies (Combs and Ervasti, 2005). 
Nonetheless, genes involved in the synthesis of this glycan structure namely 
POMT1/2 and POMGnT1 are implicated in congenital muscular dystrophy (de 
Bernabe et al., 2002; Van Reeuwijk et al., 2005; Yoshida et al., 2001). In addition, 
the analysis of α-dystroglycan isolated from the skeletal muscle of a POMGnT1 
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knock out mouse model clearly showed a loss of immunoreactivity to the IIH6 and 
VIA41 monoclonal antibodies as well as to laminin confirming the alteration in 
functional glycosylation of α-dystroglycan (Liu et al., 2006).  
Recently another unique O-mannosyl glycan was identified and was later 
demonstrated to be essential for laminin binding (Yoshida-Moriguchi et al., 2010). 
This novel O-mannosyl glycan, GalNAcβ3GlcNAcβ4(6-P-X) consists of a 
phophodiester-linked branched structures at the C6 hydroxyl residue of the initiating 
mannose (Yoshida-Moriguchi et al., 2010) and is further extended with repeating 
units of [-3-xylose-α1, 3-glucoronic acid-β1-] (Inamori et al., 2012) as illustrated in 
Figure 1.8. Mutations in the remaining three genes involved in CMD [fukutin, fukutin 
related protein (FKRP) and like-acetylglucosaminyltranferase (LARGE)] result in 
defects in the post-phosporyl modification of the O-mannose on α-dystroglycan 
(Yoshida-Moriguchi et al., 2010; Kuga et al., 2012). As a result, fukutin, FKRP and 
LARGE are thought to mediate the extension of this phosphorylated O-mannose 






Figure 1.8 Schematic representation of lamining binding glycan on α-
dystroglycan (Yoshida-Moriguchi et al., 2010; Inamori et al., 2012) 
 The critical glycan required for laminin binding consists of a phosphate 
molecule linked to the core O-mannose and is further extended with 
repeating units of [-3-xylose-α1, 3-glucoronic acid-β1-]. 
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2.4.4   Congenital muscular dystrophy 
Congenital muscular dystrophy is a family of autosomal recessive disorders 
that results in progressive weakness and wasting of skeletal muscle of which these 
conditions become apparent at birth or shortly after birth. Also known as the 
dystroglycanopathies, (Toda et al., 2003; Brockington and Muntoni, 2005; Mercuri et 
al., 2006), this disease stems from the hypoglycosylation of α-dystroglycan which 
subsequently disrupts the vital interaction between α-dystroglycan and its ligands 
within the extracellular matrix leading to the loss in skeletal muscle integrity 
(Holzfeind et al., 2002; Michele et al., 2002; Kanagawa et al., 2005). The reduction in 
glycosylation of α-dystroglycan observed in the dystroglycanopathies is based on the 
loss of immunoreactivity to the monoclonal antibodies IIH6 and VIA4-1 both of 
which,  specifically recognize the functionally glycosylated forms of α-dystroglycan 
(Brockington et al., 2002; Grewal et al., 2002; Hayashi et al., 2001; Kano et al., 2002; 
Michele et al., 2002). Studies have demonstrated that the IIH6 antibody but not VIA4-
1, blocked laminin binding which suggests that IIH6 and laminin recognize similar 
glyco-epitopes on α-dystroglycan (Ervasti and Campbell, 1993). Thus 
immunoreactivity of α-dystroglycan to IIH6 may be a more accurate reflection of its 
laminin binding capabilities.  
The dystroglycanopathies share a common pathology reflected by a reduction 
in glycosylation of α-dystroglycan on skeletal muscle biopsies as well as common 
clinical manifestations characterized by muscular dystrophy, ocular defects and 
mental retardation. However, the phenotypic severities of these disorders vary greatly 
(Muntoni et al., 2002). The severe form of dystroglycanopathies is represented by 
Walker-Warburg syndrome (WWS), Muscle-Eye–Brain (MEB) and Fukuyama 
congenital muscular dystrophy (FCMD) (van Reeuwijk et al., 2005), while the milder 
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forms are represented by limb-girdle muscular dystrophy (LGMD) and congenital 
muscular dystrophy type 1C (MDC1C) (Brockington et al., 2001; Balci et al., 2005). 
These muscular disorders occur due to mutations in confirmed or putative 
glycosyltransferases that are thought to play roles in the O-mannosylation pathway 
(Baressi and Campbell, 2006). The phenotypic severity associated with the 
dystroglycanopathies as well as the identity and function of their causative gene is 














Table 1.1 Summary of dystroglycanopathies and their causative genes  
As evident from the table above, each gene was originally described to be 
associated with a specific form of CMD. However, recent studies have revealed that 
there may be overlap with the mutations in a gene and the disease it causes. For 
instance, Fukutin mutations were identified in WWS patients (de Beranabe et al., 
2003) and in patients with a LGMD variant (Godfrey et al., 2006) while POMT1 
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mutations were implicated in LGMD2K individuals (Balci et al., 2005). POMGnT1 
mutations were also identified in patients originally clinically diagnosed with WWS 
or FCMD (Taniguchi et al., 2003). Thus refining the genotype phenotype correlation 
for this group of genes and the CMD they cause would be an important avenue for 
further research (Stalnaker et al., 2011). Another significant area for further studies is 
to identity novel genes that could be involved in the O-mannosylation pathway and 
subsequently become implicated in CMD (Stalnaker et al., 2011). This is due to the 
fact that in a recent large scale study of patients exhibiting dystroglycanopathies, 
mutations in the five genes listed in the above table featured in only 34% of patients 
(Godfrey et al., 2007). This study suggests that the majority of the patients harboured 
mutations in unknown genes (Godfrey et al., 2007). As MEB and its causative gene, 
POMGnT1 is central to this thesis, they will be discussed in detail in section 2.5.  
2.5  POMGnT1 and MEB 
2.5.1  POMGnT1 implicated in the synthesis of laminin binding glycan 
POMGnT1 has been shown to partially inhibit the postphosphoryl 
modification of the O-mannosyl glycan on α-dystroglycan. (Yoshida-Moriguchi et al., 
2010). Majority of the α-dystroglycan isolated from skeletal muscles of POMGnT1 
knockout mice exhibited binding to immobilized metal chromatography beads 
(IMAC), which is known to interact only with monoester-linked and not diester-
linked phosphorylated compounds (Yoshida-Moriguchi et al., 2010). This result 
suggests that the monoester-linked residues on α-dystroglycan isolated from 
POMGnT1 knockout mice are incapable of further modification and thus lacks the 
post-phosphoryl moiety required for laminin binding (Kuga et al., 2012). A small 
proportion of α-dystroglycan isolated from the POMGnT1 knockout mice did not 
display binding to the IMAC beads suggesting that this population retained its laminin 
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binding properties (Yoshida-Moriguchi et al., 2010). Although POMGnT1 does not 
directly modify the post-phosphoryl structure, the GlcNAc-β1,2-branch formed by 
POMGnT1 may facilitate the modification on this phosphorylated O-mannose 
structure by creating favourable circumstances of which these conditions remain 
unknown (Kuga et al., 2012).  
2.5.2 Characteristics of human POMGnT1  
The human POMGnT1 encodes a 660 amino acid type II transmembrane 
protein (Cormand et al., 1999, Yoshida et al., 2001). Computer analysis predicted 
four domains for this protein essentially the N-terminal cytoplasmic domain (Met1-
Arg37), transmembrane domain (Phe38-Ile58), stem domain (Leu59-Leu300) and a 
catalytic domain (Asn301-Thr660) (Yoshida et al., 2001; Unligil et al., 2000). 
POMGnT1 displays homology to the human UDP-GlcNAc: α-3-D-mannoside β-1,2-
N-acetylglucosaminyltransferase I (GnT-1), however, this homology is restricted to 
the first 230 amino acids of the catalytic domain of POMGnT1 (aa 301-530), 
representing the UDP-GlcNAc and Mn
2+
 binding domain of the two proteins (Manya 
et al., 2004).  Amino acids 531-562 of the catalytic domain however possesses, low 
homology to the corresponding region on GnT1 (Manya et al., 2004). This region is 
thought to represent the acceptor specific domain that recognizes a mannose peptide 
and thus is specific to POMGnT1 (Manya et al., 2004). Phylogenic analysis has 
revealed that expression of POMGnT1 is restricted to mammals such as mouse, pig 
and cattle in contrast to GnT1 which is widely distributed in mammals, insects, 
nematodes and plants (Kumar et al., 1990., Chen et al., 1999., Strasser et al., 1999). 
This suggest that the GlcNAcβ1,2Man linkage, mediated by POMGnT1 is 
biologically important for mammals only (Yoshida et al., 2001). The POMGnT1 
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protein is known to be expressed at the highest level in the heart and skeletal muscle 
(Esapa et al., 2002).  
2.5.3 Mutations in POMGnT1 leading to MEB 
Thirty four different mutations in POMGnT1 have been identified in MEB 
patients in which twenty-three resulted in premature protein truncations while eleven 
represented missense mutations (Yoshida et al., 2001., Taniguchi et al., 2003., Zhang 
et al., 2003., Akasaka-Manya et al., 2004., Diesen et al., 2004., Vervoort et al., 2004; 
Matsumoto et al., 2005; Biancheri et al., 2006; Vajsar et al., 2006; Balci et al., 2007; 
Hehr et al., 2007). Analyses from these studies demonstrated that the majority of the 
mutations lie within the catalytic domain of POMGnT1 however several mutations 
within the stem domain were also identified. Interestingly all of the mutations lead to 
a complete loss of enzymatic activity (Manya et al., 2003).  Thus POMGnT1 
represents a unique glycosyltransferase as it loses enzyme activity as a consequence 
of mutations within its stem domain (Taniguchi et al., 2003; Vervoort et al., 2004; 
Biancheri et al., 2006; Hehr et al., 2007). This is in contrast to other transferases 
where mutations outside the catalytic domain rarely reduce enzyme activity as 
observed with UDP-GlcNAc: α-6-D-mannoside β-1,2-N-
acetylglucosoaminlytransferase II (GnTII) (Wang et al., 2002) and 
galacotosyltransferase 1 (XGalT-1) (Okajima et al., 1999).  
One study proposed that mutations closer to the 5’ terminus of POMGnT1 
leads to a more severe MEB phenotype characterized by enhanced cerebral 
malformations compared to mutations at the 3 terminus of the gene (Taniguchi et al., 
2003). However more recent analysis clearly highlights that a genotype-phenotype 
correlation does not exist for MEB patients with POMGnT1 mutations (Hehr et al., 
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2007). To illustrate this, a study on 18 patients with the same homozygous Finnish 
founder mutation, demonstrated wide phenotypic variability (Diesen et al., 2004). In 
addition, two siblings with identical POMGnT1 mutations exhibited different neuro-
developmental impairment (Vervoort et al., 2004) and an extreme variability was 
observed in one family with the same POMGnT1 frameshift mutation where one 
member exhibited a moderate hydrocephalus while the other, severe hydrocephalus 
which resulted in pregnancy termination (Hehr et al., 2007). Since all existing 
mutations in POMGnT1 uniformly leads to complete loss of enzyme activity, the 
nature and location of POMGnT1 mutations does not appear to influence the 
phenotypic severity of MEB (Hehr et al., 2007). Hehr et al suggests that the wide 
clinical variability observed with MEB patients may be a consequence of other 
environmental and/or genetic factors in addition to POMGnT1 mutations.   
2.5.4 Characteristics of MEB 
Similar to the other dystroglycanopathies, MEB is generally characterized by 
congenital muscular dystrophy, ocular abnormalities and mental retardation 
(Santavuori et al., 1989). Clinically, MEB patients exhibit an early onset of muscular 
hypotonia, severely compromised motor development, severe congenital myopia and 
congenital glaucoma, hydrocephalus, mental retardation and myoclonic jerks. Infants 
with MEB are born with generalized muscle weakness which also affects facial and 
neck muscles. Recently a knockout mouse model for POMGnT1 was generated which 
demonstrated multiple developmental defects in the muscle, eye and brain and thus 
accurately reflects the human MEB disease (Liu et al., 2006). In contrast to the 
POMGnT1 knockout mice which remain viable, the knockout of POMT1 or fukutin is 
embryonically lethal suggesting a role early on in embryonic development (Takeda et 
al., 2003; Willer et al., 2004).  
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CHAPTER 3 MATERIALS AND METHODS 
3.1     Molecular biology 
3.1.1  Extraction of RNA and cDNA synthesis 
Total RNA was extracted from the siRNA transfected HEK 293 cell lines 
using RNeasy kit (Qiagen) according to the manufacturer’s instructions. For synthesis 
of first strand cDNA, 2μg of total RNA was added to 2μl of oligodT(15) (Promega) 
and topped up to 15μl of nuclease-free water followed by incubation at 72οC for 5 
minutes and cooled on ice for 2 minutes. The annealed RNA samples were then made 
up to 25μl reaction volume with 5μl Moloney murine leukemia virus (MMLV) 5 X 
reaction buffer, 1.25μ of dNTP (10mm), 1μl of RNasin Ribonuclease inhibitor, 1μl of 
Moloney murine leukemia virus reverse MMLV-RT and water. The reaction mixture 
was then incubated at 42
ο
C for 1 hour and placed on ice to terminate the reaction. All 
cDNA samples were stored at -20
ο
C until further use.  
3.1.2   Plasmid construction  
The coding region of human GOLPH3 (NCBI Reference Sequence: 
NP_071413.1) and GOLPH3L (NCBI Reference Sequence: NP_060648.2) was 
obtained from NCBI and was amplified from HeLa cDNA using nested PCR. A red 
fluorescent protein (RFP) tag was added to the N terminus of the GOLPH3 and 
GOLPH3L through the use of overlap PCR. A linker peptide, SGGGGS, which acts 
as a spacer, was placed between the RFP tag and the GOLPH3 genes. The resulting 
product was cloned into pcDNA3.1+ vector (Invitrogen, USA) using HindIII and 
Xho1 restriction sites. The coding region of GOLPH3 and GOLPH3L were also 
cloned into pGEX4T-1 (Pharmacia Biotech) using BamH1 and Xho1 restriction sites 
for expression in bacterial cells.  
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The coding region of human POMGnT1 (NCBI Reference Sequence: 
NP_060209.3) was obtained from NCBI and amplified from HeLa cDNA using 
nested PCR. His and HA tags were fused to the C terminus of POMGnT1 by 
performing an overlap PCR. A linker peptide, SGGGGS was placed between the two 
genes. The resulting product was cloned into pcDNA3.1+ vectors using BamH1 and 
Xho1 restriction sites.  
Human dystroglycan cDNA was purchased from Open Biosystems (Accession 
ID: BC014616). Amino acids 1-653 representing the signal peptide, N-terminal, 
Mucin like domain and C-terminal of α-dystroglycan was cloned out from the cDNA 
using PCR. The region corresponding to β-dystroglycan which is known to be a 
transmembrane protein was not included in the construct to allow for the secretion of 
α-dystroglycan. The Fc region from human IgG1 was fused to the C-terminus of α-
dystroglycan using overlap PCR and cloned into pcDNA3.1+ using Nhe1 and Xba1 




Fig 3.1  Schematic representation of human α-dystroglycan protein  
 An Fc tag was fused to the C-terminus of α-dystroglycan 
corresponding to amino acids 1-653. The fusion construct was then 
cloned into pcDNA3.1+ 
 
Site-directed mutagenesis of POMGnT1-His and POMGnT1-HA constructs 
were generated using the QuikChange II XL site directed mutagenesis kit (Stratagene) 
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according to the manufacturer’s instructions. All constructs were fully sequenced 
before being used for transfection. 
3.1.3   Sequencing  
All sequencing work was performed on the ABI 3100 sequencers using 
BigDye3.1 chemistry (Applied Biosystems). The cycle sequencing reaction consisted 
of 4μl of BigDye mix, 1μl of a 10μM gene-specific primer and 0.5μg of DNA 
template. Water was added to a final volume of 10μl. In addition to the gene specific 
primers, the standard sequencing primers T7 and BGH reverse primers were used to 
sequence vector templates. The sequencing PCR profile used was 96
ο
C for 30 
seconds, 50
ο
C for 15 seconds and 60
ο
C for 4 minutes. This profile was repeated for 26 
cycles.  
Ethanol precipitation was then carried out to purify the cycle sequencing 
product. 3μl of 3M sodium acetate (pH 4.6), 62.5μl of 95% ethanol and 24.5μl of 
water was added to the sequencing PCR product to make up the final volume of 
100μl. The mixture was vortexed briefly and incubated at room temperature for 15 
minutes, and then centrifuged for 14,000rpm for 20mins. The supernatant was 
removed and 250μl of 70% ethanol was added to wash the precipitate. Centrifugation 
at 14,000rpm for 5 minutes was performed before removal of the ethanol. The pellet 
was air-dried for 10 minutes and stored at -20
ο
C if the sequencing was not performed 
immediately. Purified sequencing product was dissolved in 10μl of HI-DITM 
formamide (Applied Biosystems) and denatured at 95
0
C for 5 minutes. After cooling, 
the solution was loaded onto a 96-well plate for capillary electrophoresis on the ABI 
300. Results were obtained from the Sequencing Analysis 5.1 software (Applied 
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Biosystems) as a set of DNA chromatogram and sequence text file, and checked 
against the NCBI Genbank database.  
3.2   Protein expression in bacterial cells  
For bacterial expression of recombinant proteins, the pGEX4T-1 vectors were 
transformed into E.coli BL21 (DE3) cells (Invitrogen, USA). The cells were then 
cultured at 37ºC until the OD600 value reached 0.6. Subsequently, IPTG (Invitrogen, 
USA) was added into the broth to a final concentration of 0.5mM to induce protein 
expression for 2hours at 27ºC. Cells were harvested by centrifugation and lysed in 
lysis buffer [1 X PBS, lyzozyme (1mg/ml), 0.1% Triton-X100 and protease inhibitor 
from Roche] for 30 minutes on ice. The lysate was then sonicated 8 X 10 second 
pulses with a 30 second cooling period between each pulse. The lysate was clarified at 
15,000 rpm for 20 minutes at 4
ο
C. The supernatant was then added to 50% slurry of 
gluthathione-sepharose (GSH) (Amersham Biosciences) beads for 2 hours at 4
ο
C. The 
beads were washed 4 X 5 minutes with 1 X PBS and eluted with reduced gluthathione 
(Sigma) containing protease inhibitors. The purified proteins were resolved on SDS-
PAGE gel to ascertain the purity of the proteins. The concentrations of the purified 
proteins were determined using Bradford protein assay (Bio-Rad). The purified 
proteins were then stored at -20
ο
C until further use.  
3.3   T7 phage display 
An aliquot of a T7 phage display library of human liver cDNA (Novagen) was 
pre-cleared with 100μg of GST protein immobilized on GSH beads (Amersham 
Biosciences) by incubating them together for 2 hours at room temperature. The 
supernatant was then incubated overnight at 4ºC with 100μg of GST-fused GOLPH3 
(full length) immobilized on GSH beads. All binding experiments were performed in 
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the presence of 1% bovine serum albumin. Unbound phages were washed four times 
with TBST [0.1% Tween in 10mM Tris (pH 7.4) and 150mM NaCl]. The bound 
phages were amplified in E.coli BL5615 (Novagen) which was pre-induced with 
1mM IPTG for 20minutes at 37ºC. After cell lysis, the phage lysate was clarified by 
centrifugation at 8000g for 10minutes and stored at 4ºC for use in the next selection 
round. A total of five rounds of selection were performed. PCR analysis was 
performed on amplified phages using a pair of T7 primers to ascertain the enrichment. 
The phage pool from the fourth round of amplification was panned to harvest single 
clones. Individual phage clones were picked and subjected to sequencing analysis 









Figure 3.2      Illustration of the major steps involved in T7 phage display 
Liver cDNA libraty displayed on T7 phage was pre-cleared and 
incubated with GST-GOLPH3. The bound phage was amplified in 
E.coli and the procedure repeated for an additional four times to enrich 




3.4   Mammalian Cell Culture 
3.4.1   Cell lines 
HeLa cells and HEK 293 cells were obtained from American Type Culture 
Collection (ATCC) and cultured at 37
º
C with 5% CO2 in Dulbecco’s Modified Eagle 
Medium (DMEM, Invitrogen, USA) supplemented with 10% fetal bovine serum 
(FBS) (Invitrogen, USA).  
3.4.2   Transfection of plasmid DNA 
In preparation for transfection, HeLa cells were plated at a density of 4.5 × 10
5
 
cells per well in 6-well tissue culture plates for  GST pull down assays and at 1.8 X 
10
5
 per well in 12 well plates for immunofluoresence assays. Cells were transiently 
transfected using the cationic lipid LipofectAmine 2000 (GIBCO BRL) by following 
the manufacturer’s instructions. 
3.4.3   Transfection of siRNA 
To analyze knockdown phenotypes, Golph3 siRNA was obtained from IDT 
while Golph3L, POMGnT1 and All Stars negative control siRNA (Catalog No: 
1027281) was obtained from Qiagen (Valencia, CA). siRNA were diluted to 20μM 
using RNase-free distillied water and stored at -20
ο
C until further use. Cells were 
cultured in six-well plates and transfected with siRNAs at a final concentration of 




                                              
43 
 
   
 
 
   
Table 3.1 siRNA oligonucleotide sequences.  
 siRNA oligonucleotides were purchased from IDT and Qiagen. 10nm 
of each siRNA as depicted in the table was utilized in the RNAi 
mediated analysis.  
 
3.5   Recombinant protein analysis 
3.5.1   Quantitative reverse transcription (qRT) PCR analysis 
Total RNA was extracted from the siRNA transfected HEK 293 cell lines 
using RNeasy kit (Qiagen), First strand cDNA was synthesized from 2μg of total 
RNA using Moloney murine leukemia virus reverse transcriptase (MMLV-RT) 
(Promega) and oligodT(15) (Promega). The following primers for GOLPH3, 





Table 3.2  qRT-PCR primers 
A pair of forward and reverse primers were designed for each gene and 
was used for amplification of each PCR product using qRT-PCR 
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PCR analysis was performed using ABI Prism7000qRT PCR Detection 
System (Applied Biosystems, Foster City, CA). For each reaction of 25 μl, 12.5μl of 
2X SYBR Green PCR Master Mix (Applied Biosystems) was mixed with 5 μl cDNA 
(from 2μg of total RNA) and 12.5pmol each of forward and reverse primers and  
topped up with water in a MicroAmp optical 96-well reaction plate and sealed with 
optical adhesive covers (Applied Biosystems, Framingham, MA). PCR analysis was 
performed using the ABI Prism7000 qRT PCR Detection System (Applied 
Biosystems, Foster City, CA). The PCR reaction conditions were as follows: 95
ο
C for 
10minutes, followed by 40 cycles of 95
ο
C for 15seconds and 60
ο
C for 60seconds. 
Threshold cycle (Ct) was determined using ABI Prism 7000 SDS program (Applied 
Biosystems). All reactions were run in triplicates. Relative transcript abundance was 
calculated by transforming the average, Ct values to 2-Ct and normalizing to a 
housekeeping gene, GAPDH.  
3.5.2   Western blotting  
Cell pellets harvested from adherent cells were washed twice with PBS and 
collected in 1.5ml tubes. Lysis buffer [1% IGEPAL CA-630, 20mM Tris-HCl (pH 
7.5), 150mM NaCl, 5mM EDTA and protease inhibitors from Roche] was then added 
into each tube and incubated for 5 minutes on ice. The lysate was then passed through 
a 23G needle 30 X followed by centrifugation at 4
ο
C for 20 minutes. The supernatant 
was decanted carefully into fresh tubes to remove the cell debris. The cell lysates 
were stored at -80
ο
C until further use.  
The cell lysate samples were separated on a 3-8% TA or 10% SDS-PAGE gel 
in Mini Protean-3 cell (Biorad) at 100V for 2 hours. The SDS-PAGE gels were then 
blotted onto nitrocellulose membrane (Hybond Amersham) using a Mini Trans-blot 
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cell (Biorad) at 100V for 1 hour. Transferred blots were washed with 0.1% PBST (v/v 
of Tween-20 in PBS) and then blocked in 5% non-fat milk in 0.1% PBST. The blots 
were then incubated in primary antibodies (1:1000) in 5% non-fat milk in 0.1% PBST 
overnight at 4
ο
C. The blots were then washed in fresh 0.1% PBST 4 X 10 minutes, 
followed by incubation with secondary antibody (1:10000) for 1 hour at room 
temperature. HRP (horseradish peroxidase) conjugated anti-mouse and anti-rabbit Fab 
fragments (Jackson immunosystems) were used as secondary antibodies. Following 
4X 10 minutes washes, 0.5ml of ECL reagent  (Amersham) was added to each blot, 
and fluorescence was detected on chemi-luminescent film (Lumi-film, Roche) with 
exposure times ranging from 5 minutes to 1 hour.  
3.5.3   GST pull down assays 
Wild type POMGnT1-His and mutated POMGnT1-His was transfected into 
HeLa cells. Two days following transfection, HeLa cells were lysed in lysis buffer 
[1% IGEPAL CA-630, 20mM Tris-HCl (pH 7.5), 150mM NaCl, 5mM EDTA and 
protease inhibitors from Roche] for 10minutes at 4ºC and insoluble material were 
removed by centrifugation at 15000g and 4ºC for 10minutes. 10μg of GST and GST-
GOLPH3 proteins were added to cell lysates generated from 6 x 10
6
 cells transfected 
with wild type POMGnT1 and 12 x 10
6
 cells transfected with mutated forms of 
POMGnT1. Following an incubation of 2 hour at 4ºC, 50μl of GSH beads was added 
for 2hours at 4
ο
C. Precipitates were washed 4 X 5 minutes with 1 X PBS and eluted 
with reduced gluthathione containing protease inhibitors. The resulting purified 
proteins were then subjected to SDS-PAGE followed by immunblotting with anti-His 




3.5.4   Immuno-fluorescence staining 
HeLa cells were plated on glass coverslips and grown overnight before 
transfection with the relevant HA tagged constructs. Immunofluorescent staining was 
performed according to previously published methods (Eckhardt et al, 1998; Zhao et 
al, 2006). Briefly, 2 days after transfection, cells were fixed in 4% paraformaldehyde 
(Sigma, USA), permeablized in 0.1% TritonX-100 (Sigma, USA), and blocked in 
10% normal goat serum (Invitrogen, USA) for 30minutes. Cells were then incubated 
with a 1:500 dilution of mouse anti-HA monoclonal antibody (Sigma) and a 1:300 
dilution of rabbit anti-giantin (Abcam) or a 1:160 dilution of rabbit anti-GOLPH3 
(Abcam) in PBS with 1% BSA for 1hour. Cells were washed three times with PBS 
and subsequently incubated with goat anti-mouse conjugated with Alexa Fluor 488 
and goat anti-rabbit conjugated with Alexa Fluor 594 (Invitrogen, USA) in PBS with 
1% BSA for 1 hour. Cells were washed three times with PBS before mounting on 
glass slides with a Prolong Gold Antifade mounting medium (Invitrogen, USA). 
Fluorescence images were obtained using a CarlZeiss META confocal microscope.  
3.5.5   FACS analysis  
For cell surface staining of α-DG with mAb IIH6 (Santa Cruz) and mAb 
VIA41 (Santa Cruz), HEK 293 cells were detached with enzyme–free dissociation 
solution (Sigma, USA). The cells were then washed with PBS and blocked with 
1%BSA/PBS for 15 minutes on ice. This was followed by incubations with mAb IIH6 
(1:100) or mAb VIA4-1 (1:100) in 1%BSA/PBS for 1 hour on ice. Cells were then 
washed twice in PBS and labelled with goat anti-mouse conjugated with Alexa Fluor 
488 (1:500) (Invitrogen, USA) in 1%BSA/PBS for 45 minutes on ice in the dark. 
Following two washes with PBS, the stained cells were analyzed with a FACSCalibur 
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flow cytometry (Becton Dicksinson, San Jose CA) using Cell Quest Software. Image 



















CHAPTER 4 IDENTIFICATION OF A NOVEL GOLPH3 
INTERACTING PARTNER THROUGH THE 
USE OF A T7 PHAGE DISPLAY 
4.1      Introduction 
GOLPH3 represents a highly conserved protein found across the eukaryotic 
lineage. The GOLPH3 homolog in yeast, Vps74p was shown to interact directly with 
several cis and medial mannnosyltransferases as well as with components of the 
COP1 coat (Schmitz et al., 2008; Tu et al., 2008). Vps74p was thus postulated to act 
as an adaptor that facilitates mannosyltransferase incorporation into retrograde COP1 
vesicles and ultimately controls the steady state distribution of these enzymes by 
anchoring them at the yeast Golgi (Schmitz et al., 2008; Tu et al., 2008). 
Consequently, the deletion of vps74 was shown to have deleterious effects on both 
N- and O-linked mannosylation in yeast (Schmitz et al., 2008; Tu et al., 2008). Due 
to the high degree of conservation between the GOLPH3 family of proteins, the 
mammalian GOLPH3 protein was speculated to perform a similar function at the 
Golgi. In support of this, both GOLPH3 and its isoform GOLPH3L were shown to 
be able to partially correct for phenotypic defects observed in vps74 cells (Tu et al., 
2008).  
Extensive research on GOLPH3 has implicated the protein in various 
biological proceses. GOLPH3 is now regarded as a bona fide oncoprotein that is 
upregulated in various forms of cancer (Scott et al., 2009., Kunigou et al., 2011., Li 
et al., 2011). The molecular mechanism of its oncogenic activity was shown to be 
associated with the enhanced activation of mammalian target of rapamycin (mTOR) 
signalling (Scott et al., 2009). Another study by Dippold et al linked GOLPH3 to 
mammalian protein trafficking, achieved through dual interaction with 
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phophatidylinositol-4-phosphate (PtsIns(4)P) on Golgi membranes as well as with 
myosin18A (MYO18A) (Dippold et al., 2009). The PtdIns(4)P-GOLPH3-MYO18A 
linkage was demonstrated to be critical for generating a tensile force that is required 
for efficient trafficking of proteins from the Golgi to the plasma membrane (Dippold 
et al., 2009). In yet another study, GOLPH3 was shown to physically interact and 
co-localize with Vps35 (Scott et al., 2009), a member of the cargo-recognition 
complex of the retromer involved in the retrograde transport of transmembrane 
receptors between endosome and the TGN (Bonifacino et al., 2008). This result 
suggests that GOLPH3, together with Vps35 mediates the recycling of important 
molecules from the endosome to the TGN (Scott et al., 2009). However the most 
relevant study to our work was that done by Ali et al in which they unveiled an 
interaction between GOLPH3 and a mammalian glycosyltransferase, specifically the 
Core 2 N-acetlyglucosaminyltransferase 1 (C2GnT1), implicated in the generation of 
the core 2 associated sialyl Lewis x (C2-O-sLe
X
) glycan structure (Ali et al., 2012). 
In addition to demonstrating physical interaction with C2GnT1, GOLPH3 was also 
shown to be critical for maintaining the Golgi localization of C2GnT1. 
Susbequently, the loss of GOLPH3 correlated with the reduced synthesis of the C2-
O-sLe
X
  glycan (Ali et al., 2012). These results lend further credence to the view that 
GOLPH3 carries out an analogous role to Vps74p in a mammalian system.  
The GOLPH3 isoform GOLPH3-like (GOLPH3L) displays 55% sequence 
identity with GOLPH3 (Wu et al., 2000). Both proteins share a central conserved 
core domain consisting of approximately 200 amino acids but are flanked by 
variable N- and C- terminal domains (Wu et al., 2000). In contrast to the various 
biological functions that GOLPH3 is implicated in, the function of its isoform 
GOLPH3-like (GOLPH3L) is unknown. Additionally, GOLPH3L is known to be 
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under-expressed in mammalian cells (Nakashima-Kamimura et al., 2005). 
Interesingly however, the human GOLPH3L was more effective at restoring the 
Golgi localization of the yeast mannosyltransferase Kre2p in vps74 cells when 
compared to GOLPH3 (Tu et al., 2008).  
Our aim in this chapter was to identify novel GOLPH3 binding partners in an 
attempt to precisely define the function of the GOLPH3 proteins in glycosylation. We 
have employed the use of a T7 phage display for this purpose. The rationale for using 
this system as opposed to other screening platforms will be reviewed in detail in the 
discussion section of this chapter. Through the use of a T7 phage dislplay platform, 
we have identified a novel interaction between the GOLPH3 proteins and POMGnT1, 













4.2   T7 phage display as a screening platform to identify novel GOLPH3   
interactions 
 
Full length human GOLPH3 and GOLPH3L cDNA were cloned from HeLa 
cells using nested PCR. The cDNAs was then inserted into pGEX-4T vector 
downstream of a GST tag. The vector was expressed in the BL21 strain of E.coli 
under optimized conditions using 0.5mM IPTG induction followed by incubation for 
a period of 2 hours at 27
ο
C. Following lysis, an aliquot of the crude lysate was 
resolved on SDS-PAGE gel and stained with Coomassie to assess for the expression 
of the GOLPH3 proteins. Dominant bands of ~56kDa (Figure 4.1) was observed on 









Figure 4.1 Expression of GST-GOLPH3 proteins in E.coli  
Following induction of protein expression in E.coli, aliquots of the 
GST, GST-GOLPH3 and GST-GOLPH3L transformed bacterial 
lysates were resolved on SDS-PAGE gel and stained with Commasie. 
Arrows indicate putative GST (26kDa) and GST-GOLPH3/L (~56 
kDa) bands.  
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The crude lysate was then subjected to affinity chromatography using GSH 
beads. The purified proteins were resolved on SDS-PAGE and stained with Comassie. 













Figure 4.2  Affinity purification of GST-GOLPH3 proteins 
Bacterial lysates of GST, GST-GOLPH3 and GST-GOLPH3L were 
purified using GSH beads. Following elution with reduced 
gluthathione, the proteins were resolved on an SDS-PAGE gel and 
stained with Comassie to assess the purity of the GST proteins. 
 
The purified GST-GOLPH3 and GST-GOLPH3L proteins were used as bait in 
a phage display screen that was carried out on a human liver cDNA library displayed 
on a T7 phage vector. In these commercially obtained vectors, target sequences were 
cloned in frame to the C-terminus of the 10B capsid of the T7 phage using EcoR 1 
and HindIII restriction sites (Figure 4.3). A mid-copy T7 phage vector (T7Select10-
3b) with a copy number of 5-15/per phage was utilized in our screen. The use of a 
mid-copy vector allowed for the selection of proteins/peptides that bound to the bait 
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protein (GST-GOLPH3) with high affinity thus ensuring that only strong GOLPH3 
binders were obtained. Another unique feature of the T7Select10-3b phage vectors are 





Figure 4.3  Cloning region of T7 Select 10-3b 
T7 upstream and downstream primers that bind to sequences flanking 
the cloning site were utilized to identify peptide binding phages.  
 
Five rounds of affinity selection were performed to enrich over unspecific 
binders and importantly, to select for peptides with increasingly higher affinity to 
GOLPH3 and GOLPH3L. The enrichment after each round was ascertained by 
performing PCR using T7 upstream and downstream primers (T7SelectUP primer and 
T7SelectDOWN primer) which bind to regions flanking the cloning site as indicated 





 round of selection suggesting that specific GOLPH3 and GOLPH3L 















Figure 4.4 PCR demonstrating enrichment of GOLPH3 binding phage pool
  
GST-GOLPH3 was used as the bait in a T7 phage display screen that 
was carried out on a human liver cDNA library. Five rounds of 
biopanning were performed. Enrichment after each round was assessed 

















Figure 4.5 PCR demonstrating enrichment of GOLPH3L binding phage pool
  
GST-GOLPH3L was used as the bait in a T7 phage display screen that 
was carried out on a human liver cDNA library. Five rounds of 
biopanning were performed. Enrichment after each round was assessed 









4.3   Identification of peptides interacting with GOLPH3 and GOLPH3L 
In order to elucidate the identity of the peptides that interacted with GOLPH3 
and GOLPH3L, the phage pool from the 4
th
 round of biopanning was panned to 
harvest single clones. Subsequently, the inserts of the T7 binding phage was 
sequenced using T7 upstream primers to reveal epitopes recognized by the GOLPH3 
proteins. Sequencing analysis revealed that a dominant peptide was obtained as 50% 
of the clones contained an identical peptide corresponding to several amino acids 
present on POMGnT1 (Figure 4.6, top panel). Our phage display result demonstrating 
that only 9 amino acids on POMGnT1 are required to interact with GOLPH3 is 
surprising, however this can be attributed to the fact that cDNA libraries have 
unpredictable reading frames and as a consequence demonstate frequent shifts in 
reading frames. Thus, results from a T7 phage display usually represent peptide 
motifs as opposed to entire peptide sequences. The identification of only 9 amino 
acids on POMGnT1 required for interaction with GOLPH3 reflects a similar situation 
in many other proteins, where only a small number of residues are responsible for the 
change in free energy that subsequently mediates binding (Willats, 2002).
 
To illustrate 
this point, only 8 out of the 217 residues in human growth hormone accounts for 
majority of its binding energy
 
(Rodi and Makowski, 1999).  
Further analysis revealed that the amino acids present on the GOLPH3 binding 
phage peptide were restricted to the stem domain of POMGnT1 (Figure 4.6, bottom 
panel). Importantly, the same peptide was obtained when GST-GOLPH3L was used 
as the bait protein, although it represented only 10% of the clones. Nontheless, this 
result is significant given the high degree of homology between GOLPH3 and 
GOLPH3L. Other peptides of interest that were identified in the T7 phage display 










Figure 4.6   Identification of a dominant GOLPH3 binder 
(Top panel) The dominant GOLPH3 binding peptide corresponded to 
specific amino acids on POMGnT1 (highlighted in red). (Lower panel) 
Schematic representation of POMGnT1. Amino acids present on the 













Table 4.1 Identification of GOLPH3 binding peptides  
The GOLPH3 binding peptides identified in the T7 phage display were 











Table 4.2 Identification of GOLPH3L binding peptides  
The GOLPH3L binding peptides represented glycoytransferases from 
different glycosylation pathways. 
 
4.3.1   Glycosylation related genes 
The dominant GOLPH3 binder in our screen represented a peptide 
corresponding to a several amino acids on POMGnT1. Importantly, the same peptide 
was obtained when GST-GOLPH3L was used as the bait protein. POMGnT1 is 
involved in a unique type of mammalian glycosylation; O-mannosylation which is 
restricted to a limited group of mammalian glycoproteins, paticularly α-dystroglycan. 
POMGnT1 plays a critical role in O-mannosylation as it is responsible for catalyzing 
a GlcNacβ1-2Man linkage on α-dystroglycan (Yoshida et al, 2001; Zhang et al, 
2002). Consequently, mutations in this gene results in abnormal glycosylation of α-
dystroglycan leading to a specific type of congenital muscular dystrophy termed 
muscle-eye brain disease (MEB) (Yoshida et al., 2001; Taniguchi et al., 2003; Zhang 
et al., 2003; Akasaka-Manya et al., 2004;  Diesen et al., 2004;  Vervoort et al., 2004; 
58 
 
Matsumoto et al., 2005; Biancheri et al., 2006; Vajsar et al., 2006; Balci et al., 2007; 
Hehr et al., 2007). This novel interaction was further verified in an independent 
system, thus linking GOLPH3 to O-mannosylation (see Chapter 5). 
In addition to POMGnT1, the T7 phage display also unveiled interactions 
between GOLPH3 and other mammalian glycosyltransferases. Interestingly, both 
GOLPH3 and GOLPH3L interacted with different members of the N-
acetlygalactosaminyltransferase (GalNAc) family. GOLPH3 identified a peptide on 
GalNAc-T12 (Table 4.1), while GOLPH3L interacted with GalNAc-T5 and GalNAc-
T9 (Table 4.2). These enzymes are involved in the initiation of mammalian O-linked 
glycosylation by mediating the transfer of N-acetylgalactosamine (GalNac) to Ser or 
Thr residues on newly synthesized polypeptides. This result could suggest that 
GOLPH3 may be implicated in O-linked glycosylation. This finding is reinforced by a 
recent study by Ali et al, who demonstrated that GOLPH3 is indeed involved in O-
glycosylation as it interacts with Core 2 N-acetylglucosaminlytransferase 1 
(C2GnT1). C2GnT1 is involved in the conversion of core 1 O-glycans to core 2 by 
mediating the attachement of GlcNAc to GalNAc resulting in the synthesis of the core 
2 associated Lewis x (C2-O-sLe
x
) glycan.  
Another glycoysltransferase that was identified in our screen was human 
glycosyltransferase-like domain containing 1 (GTDC1). This novel gene was 
originally cloned from a human fetal cDNA library by high throughput cDNA 
sequencing (Zhao et al., 2004), and was again identified in a subsequent 
bioinformatics study, designated as Hmat-Xa (Shimono et al., 2011). Although the 
function of GTDC1 has not been elucidated, it is known to possess a partial 
glycoysltransferase group 1 domain which displays homology to human 
mannosyltransferase II/III and mannosyltransferase IV/V (Shimono et al., 2011). 
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These enzymes are implicated in the initial steps of the N-glycosylation pathway, 
specifically they are involved in the stepwise addition of mannose residues onto the 
dolichol-linked oligosaccharide to generate the Man5GlcNAc2-PP-dolichol 
intermediate (Rind et al., 2010). The identification of an interaction between 
GOLPH3L and GTDC1 could implicate the former in the synthesis of lipid-linked 
oligosaccharides, however this interaction was not further verified due to the limited 
information available on GTDC1.  
4.3.2  Golgi matrix proteins 
As GOLPH3 is known to associate with the Golgi, it is thus reasonable to 
speculate that GOLPH3 interacts with other Golgi resident proteins. In line with this, 
the T7 phage display platform revealed an interaction between GOLPH3 and  
GM130, a cis-Golgi matrix protein that is thought to play a role in maintenance of the 
Golgi structure (Nakamura et al., 1995).  Additionally, it was shown to participate in 
the transport of proteins and lipids in the secretory pathway (Nakamura, 2010). A 
recent study by Dippold et al demonstrated that GOLPH3 may be implicated in both 
these roles. In this study, the knockdown of GOLPH3 resulted in the dilation of the 
trans Golgi cisternae and significantly impaired the transport of a GFP tagged 
temperature sensitive Vesicular Stomatitis Virus Glycoprotein (ts045-VSVG-EGFP) 
from the Golgi to the plasma membrane (Dippold et al., 2009). Thus the GOLPH3-
GOLGA2 interaction identified in the T7 phage display screen could hold some 
relevance.  
4.3.3  Cancer related genes  
GOLPH3 was recently identified as an oncoprotein and is targeted for copy-
number gain/amplification in diverse human cancers (Scott et al., 2009). The 
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molecular mechanism of its oncogenic activity was shown to be linked to the 
enhanced activation mTOR signalling (Scott et al., 2009) which is known to control 
cell growth, proliferation and survival (Wullschleger et al., 2006). In our T7 phage 
display screen, we identified the translationally controlled tumour protein (TCTP) as a 
potential GOLPH3 interacting partner. The protein is thought to be critical for cell 
growth and differentiation (Gachet et al., 1999; Kamath et al., 2003; Yarm et al., 
2002) and studies have demonstrated its association with cancer. During the reversion 
of malignant cancer cells, TCTP levels are significantly reduced (Tuynder et al., 
2002). Additionally inhibition of TCTP expression leads to the suppression of the 
malignant phenotype (Tuynder et al., 2002). Thus our finding may lend further 













4.4  Discussion  
T7 phage display system was used in this study to circumvent limitations that 
are inherent in the screening platforms previously utilized to identify novel GOLPH3 
binding partners. Large scale immunoprecipitation followed by mass spectrometry 
was used in the study by Dippold et al which led to the identification of an interaction 
between GOLPH3 and MYO18A. However, such approaches are known to be heavily 
biased towards proteins of high abundance (von Mering et al., 2002). As a 
consequence, interactions between proteins of low abundance are likely to go 
undetected. A case in point is POMGnT1 which demonstrates low endogenous levels 
in human cell lines such as HeLa (Xiong et al., 2006). Such differences in protein 
abundance can be avoided in phage display libraries due to the fact that interacting 
proteins are expressed at similar levels. Another limitation of IP is that such 
approaches may result in the loss of potential candidates due to protein insolubility 
and transient or weak interactions (Roux et al., 2012).  
The interaction between GOLPH3 and Vps35 was identified through the use 
of a yeast two-hybrid platform (Scott et al., 2009). In such platforms, interacting 
proteins require translocation into the nucleus to activate transcription of a reporter 
gene. Thus, such strategies are rendered inappropriate for assessing interactions 
between membrane bound proteins (Bruckner et al., 2009). As GOLPH3 is a 
peripheral membrane protein and its potential interacting partners are speculated to be 
glycoysltransferases (transmembrane proteins), the yeast two-hybrid strategy did not 
represent a suitable platform for assessing GOLPH3 interactions.  
Despite the obvious attributes the T7 phage display system possesses over the 
two previously utilized strategies, it also has its limitations. The phage display system 
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identifies binary interactions between two proteins and is thus unable detect native 
multi-protein complexes, a feature which is characteristic of the IP/mass spectrometry 
approach. Thus interactions identified by T7 phage display only represent a fraction 
of the total interactions possible for that particular protein.  Additionally, protein 
interactions in this system are assessed in a cellular environment that is not native to 
the respective proteins often leading to the absence of proper post-translational 
modification. Thus, the T7 phage display system may be unsuitable for proteins that 
undergo extensive post-translational modifications such as glycosylation. As the only 
known GOLPH3 modifications to date are limited to phosphorylation and 
myristylation (Wu et al., 2000) the T7 phage display represented an attractive 
platform to elucidate novel GOLPH3 interactions.  
The identification of the interaction between GOLPH3 and POMGnT1 was 
compelling as the activity of POMGnT1 is known to be restricted to O-mannosylation 
which is commonly known as a yeast type modification (Nakajima-Ballou, 1974; 
Raizada et al., 1975; Hayette et al., 1992; Herscovics and Orlean, 1993). Given the 
fact that the GOLPH3 homologue, Vps74p was also found to interact with yeast 
glycosyltransferases (Schmitz et al., 2008; Tu et al., 2008), the identified interaction 
between GOLPH3 and POMGnT1 reinforces the conserved nature of the GOLPH3 
family of proteins in mediating yeast type modifications. In the same screen, 
alongside POMGnT1, we also identified other glycosyltransferases that are implicated 
in the initiation of mammalian O-linked glycosylation. This finding correlates well 
with a recent finding by Ali et al., who demonstrated that GOLPH3 is indeed involved 
in O-glycosylation as it interacts with Core 2 N-acetylglucosaminlytransferase 1 
(C2GnT1). It is noteworthy that glycosyltranferases involved in N-linked 
glycosylation were not identified in our screen which is consistent with a previous 
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report by Dippold et al in which they showed that GOLPH3 does not have the ability 
to interact with several N-linked glycosyltransferases specifically α-mannosidase II, 
β-1,4-galactosyltransferase and α-2,6-sialyltransferase (Dippold et al., 2009). In 
addition, the localization of these specific transferases were not affected by the 
reduction in levels of GOLPH3 leading to the conclusion that the role of Vps74p in 
maintaining the Golgi localization of glycosyltransferases is restricted to yeast 
(Dippold et al., 2009).   
Another compelling feature of this newly identified interaction can be 
attributed to the potentially similar tissue distribution of GOLPH3 and POMGnT1.  A 
novel splice variant of the GOLPH3 mouse homolog, Gmx33 was recently identified 
(Nagano-Ito et al., 2007). mRNA levels of the variant (Gmx33V) was shown to be 
exclusively expressed in skeletal muscles which is in striking contrast to the full 
length form where expression levels were found to be similar in all tissues tested 
(Nagano-Ito et al., 2007). These findings led to the conclusion that the Gmx33V 
protein could play significant role in skeletal muscle of which its function remains to 
be identified (Nagano-Ito et al., 2007). Importantly, the variant form was also 
identified in human cell lines such as HeLa (Nagano-Ito et al., 2007), and thus could 
be significantly relevant to our work. Similar to the Gmx33V, the POMGnT1 protein 
is known to be expressed at high levels in skeletal muscle (Esapa et al., 2002)  
Given the dominance of the POMGnT1 peptide obtained in the T7 phage 
display using GOLPH3 as the bait protein as well as the fact that this interaction is 
conserved for GOLPH3L, we proceeded to verify the interaction between the 
GOLPH3 proteins and POMGnT1 in an independent system which will be discussed 
in detail in the next chapter.  
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CHAPTER 5  ASSESSING THE ROLE OF GOLPH3 IN 
MAINTAINING POMGnT1 GOLGI 
LOCALIZATION 
5.1       Introduction  
The human POMGnT1 encodes a 660 amino acid type II transmembrane 
protein and is predicted to have four domains, essentially the N-terminal cytoplasmic 
tail (Met1-Arg37), transmembrane domain (Phe38-Ile58), stem domain (Leu59-
Leu300) and a catalytic domain (Asn301-Thr660) (Yoshida et al., 2001; Unligil et al., 
2000). POMGnT1 catalyses the second step in the O-mannosylation pathway by 
mediating the transfer of N-actetylglucosamine (GlcNAc) from UDP-GlcNAc onto 
the mannose in the 2-OH position (Yoshida et al., 2001; Zhang et al., 2002). The 
GlcNacβ1-2Man linkage catalyzed by POMGnT1 is known to be unique to mammals 
as POMGnT1 does not demonstrate homology to enzymes in any other genome 
(Yoshida et al., 2001). A recent glycomic analysis in a POMGnT1 null mouse model 
demonstrated a clear absence of classically extended O-mannosyl glycans, suggesting 
that no compensatory glycosyltransferases exists for POMGnT1 (Stalnaker et al., 
2011). This result highlights the critical role of POMGnT1 in the O-mannosylation 
pathway. 
POMGnT1 is known to localize to the Golgi, however the mechanism 
maintaining this localization is unclear. The localization of glycosyltransferases at the 
Golgi compartment is a pre-requisite for these enzymes to perform their designated 
role in glycosylation. Consequently, defects in function or localization of 
glycosyltransferases are known to severely impact human conditions such as 
congenital disorders of glycosylation (CGD) (Jaeken and Matthijs, 2007) or 
congenital muscular dystrophy (CMD) (Mendell et al., 2006). As such, elucidating 
the molecular mechanisms responsible for glycoysltransferase Golgi localization is 
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critical. In this chapter, we assessed the role of GOLPH3 in maintaining the Golgi 
localization of POMGnT1. This was determined by analyzing the subcellular 
localization of POMGnT1 following the disruption of the POMGnT1-GOLPH3 
interaction as well as the RNAi mediated knockdown of GOLPH3. Our hypothesis 
that GOLPH3 determines the localization of POMGnT1 stems from the results 
observed in yeast where the GOLPH3 homolog, Vps74p was observed to to play a 
critical role in controlling the steady state distribution of specific 
mannosyltransferases by anchoring them at the Golgi (Schmitz et al., 2008; Tu et al., 
2008). In addition, a recent study has showed that the human GOLPH3 protein is 
important for mediating interactions with and maintaining the Golgi localization of 
C2GnT1 (Ali et al., 2012), thus lending further credence to the view that GOLPH3 
carries out an analogous role to Vps74p in a mammalian system. 
In this chapter, we also employed in situ methods (immunofluorescence) 
coupled with biochemical methods (pull-down assay) to validate the novel interaction 
between GOLPH3 and POMGnT1 as identified in the phage display screen. 
Immunocytochemistry allows insight into possible subcellular colocalization of 
proteins but does not provide conclusive evidence for direct interaction. In contrast, 
the pull-down method permits the study of physical protein interactions. Thus both 
methods are complementary allowing for the verification of this previously 






5.2  Assessment of physical interaction between GOLPH3 proteins and 
POMGnT1 
To verify the binding interaction between the GOLPH3 proteins and 
POMGnT1 as identified in the phage display, we performed a GST pull down assay 
using GST-GOLPH3 and GST only proteins. Specifically, lysates of HeLa cells 
expressing POMGnT1-His were incubated with the respective purified GST proteins 
and immobilized on GSH beads. Following elution, the precipitates were probed with 
anti-His antibodies to detect the presence of POMGnT1. As seen in Figure 5.1a, GST-
GOLPH3 pulled down POMGnT1-His from HeLa cells. In contrast, no binding was 
observed for GST alone. We also assessed for possible interaction between 
GOLPH3L and POMGnT1 and demonstrate that the interaction was conserved for 
GOLPH3L (Figure 5.1b). This result supports a physical interaction between the 
GOLPH3 proteins and POMGnT1.  






Figure 5.1  Assessment of GOLPH3 and GOLPH3L interaction with 
POMGnT1 
GST-GOLPH3 (a) and GST-GOLPH3L (b) fusion proteins were 
incubated with lysates of HeLa cells expressing POMGnT1-His and 
immobilized on GSH beads. The top panel shows an anti-His blot to 
visualise bound POMGnT1 and the bottom panel shows an anti-GST 
blot of the immobilized GST proteins. Both GOLPH3 and GOLPH3L 
displayed interaction with POMGnT1. 
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5.3  Assessment of subcellular distribution of the GOLPH3 proteins and 
POMGnT1 
It is necessary for two interacting proteins to co-localize at a specific 
subcellular compartment. Thus to ensure that POMGnT1 is able to achieve co-
localization with the GOLPH3 proteins, we performed immunofluorescence assays. 
Analysis of HeLa cells expressing POMGnT1-HA showed that POMGnT1 localized 
to the Golgi as depicted by the co-localization with the Golgi marker, giantin (Figure 
5.2). Importantly, the co-transfection of the HA tagged POMGnT1 together with RFP-
GOLPH3 showed that both proteins co-localized (Figure 5.3, top panel). A similar 
result was observed for RFP-GOLPH3L (Figure 5.3, bottom panel). Thus the 





Figure 5.2 Subcellular localization analysis of POMGnT1  
POMGnT1-HA was transiently transfected into HeLa cells following 
which fixed cells were stained with anti-HA (green) and anti-giantin 
(red) specific antibodies. Nuclei were counterstained with DAPI (blue). 
The enlarged images represent the area indicated by the dotted boxes. 






















Figure 5.3 Assessement of co-localization of POMGnT1 and the GOLPH3 
proteins 
POMGnT1-HA was co-transfected with RFP-GOLPH3 (top panel) or 
RFP-GOLPH3L (bottom panel) and fixed cells were stained for HA 
(green) and DAPI (blue). The enlarged images represent the area 
indicated by the dotted boxes. POMGnT1 co-localized with both 
GOLPH3 and GOLPH3L.   
 
5.4 Effect of disrupting the GOLPH3-POMGnT1 interaction on POMGnT1 
localization   
Specific amino acids within the stem domain of POMGnT1 were identified in 
the T7 phage display (Figure 4.6) as important for mediating interactions with 
GOLPH3 and potentially for determining the Golgi localization of POMGnT1. To 
determine the functional significance of these key residues in maintaining POMGnT1 
Golgi localization, we substituted the nine amino acids with alanine residues 
(POMGnT1 9A, Figure 5.4) and assessed the subcellular distribution of the protein 
via immunofluorecence assays. In an attempt to identify the exact amino acid on 
POMGnT1 responsible for determining its Golgi localization, we constructed a panel 
of mutants by replacing several amino acids within a cluster with alanine residues 
thus generating POMGnT1-HLK, POMGnT1-LR and POMGnT1-GWTW (Figure 
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. The panel 







Figure 5.4 Generation of POMGnT1 mutants for subcellular localization analysis                                                            
A series of mutants was constructed via site-directed mutagenesis. 
Nine key amino acids within the POMGnT1 stem domain were 
substituted with alanine (POMGnT1 9A). Amino acids within a cluster 
were also substituted in a similar manner (POMGnT1-HLK, 
POMGnT1-LR and POMGnT1-GWTW) Single point mutations were 






As shown in Figure 5.5, substitution of the 9 amino acids within POMGnT1 
(POMGnT1 9A), resulted in the failure of the protein to localize to the Golgi as 
depicted by the inability of the protein to overlap with the Golgi marker, giantin. The 
substitutions of a smaller subset of amino acids, (POMGnT1-HLK) resulted in the 
partial Golgi mislocalization as a small proportion of the protein was observed to be 
relocated out of the Golgi when comparisons were made to the subcellular 
localization of the wild type POMGnT1 protein as shown in the top panel of Figure 
5.5. POMGnT1-LR and POMGnT1-GWTW also failed to localize to the Golgi as 
observed by the inability of the proteins to overlap with giantin (Figure 5.5). Taken 
together, these results indicate that all the three amino acids clusters identified in the 
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T7 phage display are important in mediating the Golgi localization of POMGnT1. 
Interestingly, we found that a single amino acid substitution at L
193
 (POMGnT1 
L193A), resulted in the distinct mislocalization of the POMGnT1 protein observed by 













Figure 5.5 Analyzing the subcellular localization of a panel of POMGnT1 
mutants  
HeLa cells expressing several HA tagged POMGnT1 mutant constructs 
(Figure 5.4) were fixed and stained for HA (green), giantin (red) and 
DAPI (blue). The localization of wild type POMGnT1 is illustrated in 
the top panel. POMGnT1 9A, POMGnT1-LR, POMGnT1-GWTW and 
POMGnT1 L193A failed to localize to the Golgi. POMGnT1-HLK 
demonstrated partial Golgi mislocalization.  
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We next examined whether the inability of the POMGnT1 mutants to localize 
to the Golgi correlated with their inability to interact with the GOLPH3 proteins. We 
assessed the GOLPH3 and GOLPH3L binding capabilities of POMGnT1 9A and 
POMGnT1 L193A as these two POMGnT1 mutants demonstrated distinct Golgi 
mislocalization. POMGnT1 9A and POMGnT1 L193A were fused to a His tag and 
the expression constructs were transfected into HeLa cells. The wild type POMGnT1 
was separately transfected as a positive control. The lysates were then incubated with 
the respective purified GST GOLPH3 and GOLPH3L proteins followed by 
immobilization on GSH beads and the precipitates probed with anti-His antibodies to 
detect POMGnT1. As shown in Figure 5.6a, GST-GOLPH3 failed to pull down 
POMGnT1 9A from the cells. Similar analyses with the GST-GOLPH3L protein 
produced the same result (Figure 5.6b).  






Figure 5.6 Assessment of GOLPH3 and GOLPH3L interaction with 
POMGnT1 9A                                                                                                
GST-GOLPH3 (a) and GST-GOLPH3L (b) fusion proteins were 
incubated with lysates of HeLa cells expressing His tagged POMGnT1 
WT and POMGnT1 9A. The top panel shows an anti-His blot to 
visualise bound POMGnT1 and the bottom panel shows an anti-GST 
blot of the immobilized GST proteins GST-GOLPH3 and GST-
GOLPH3L failed to interact with POMGnT1 9A.  
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In addition, we found that the single amino acid substitution at L
193
 on 
POMGnT1 (POMGnT1 L193A) resulted in significantly reduced binding to GOLPH3 
(Figure 5.7a) and GOLPH3L (Figure 5.7b). Although not examined, we speculate that 
the POMGnT1-LR and POMGnT1-GWTW would also demonstrate reduced 
GOLPH3 and GOLPH3L binding capabilities due to the inability of the POMGnT1 
mutants to localize to the Golgi (Figure 5.5).  






Figure 5.7   Assessment of GOLPH3 and GOLPH3L interaction with 
POMGnT1 L193A                                                             
 
 
GST-GOLPH3 (a) and GST-GOLPH3L (b) fusion proteins were 
incubated with lysates of HeLa cells expressing His tagged POMGnT1 
WT and POMGnT1 L193A. The top panel shows an anti-His blot to 
visualise bound POMGnT1 and the bottom panel shows an anti-GST 
blot of the immobilized GST proteins The GOLPH3 proteins 
demonstrated reduced binding to POMGnT1 L193A.   
 
We have thus mapped the GOLPH3 interaction domain to specific amino 
acids in the stem domain on POMGnT1. In addition, we show that a single amino acid 
L
193
 on POMGnT1 may be critical for this role. Importantly, we showed that the loss 
of GOLPH3 interaction correlated with the inability of POMGnT1 to achieve Golgi 
localization.   
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5.5  Examining the impact of GOLPH3 and GOLPH3L knockdown on 
POMGnT1 localization  
 
In an effort to further support the finding that GOLPH3 is critical in 
maintaining the Golgi localization of POMGnT1, we employed RNAi based 
interference to reduce the expression levels of both GOLPH3 and GOLPH3L 
followed by the assesement of the subcellular localization of POMGnT1-HA. Due to 
the existence of a GOLPH3 variant (GOLPH3V) as described in section 2.3.4 and 
knowing that GOLPH3V exists in HeLa cells (Nagano-Ito et al., 2007), we utilized a 
siRNA that targeted the first 84 amino acids of GOLPH3 which allowed for the 
knockdown of both variant and full length form of the GOLPH3 protein. siRNA 
targeting GOLPH3 and GOLPH3L were co-transfected into HeLa cells followed by 
the transfection of POMGnT1. The cells were then stained with anti-GOLPH3 
antibodies to assess for GOLPH3 knockdown as well as anti-HA antibodies to 
determine the subcellular localization of the HA tagged POMGnT1. The knockdown 
of the GOLPH3 protein following siRNA treatment resulted in a reduction in intensity 
of the anti-GOLPH3 antibody immunofluorescence (red stain, Figure 5.8). The 
assessment of subcellular localization of POMGnT1-HA in these specific cells 
showed that depletion of GOLPH3 shifted the localization of POMGnT1 out of the 
Golgi (dashed arrows in Figure 5.8) whereas the Golgi localization of POMGnT1 was 
maintained in cells treated with control siRNA (top panel) or in cells which failed to 
demonstrate efficient GOLPH3 knockdown following siRNA treatment (solid arrows 
in Figure 5.8). Taken together, these data demonstrate that the GOLPH3 proteins 














Figure 5.8 Subcellular localization of POMGnT1 following GOLPH3 and 
GOLPH3L knockdown  
HeLa cells were serially transfected with control siRNA (upper panel) 
or GOLPH3 and GOLPH3L siRNA (lower panel), followed by vector 
expressing POMGnT1-HA. Cells were fixed and stained for GOLPH3 
(red), HA (green) and DAPI (blue). The Golgi localization of 
POMGnT1 was maintained in cells expressing GOLPH3 (solid 
arrows). The knockdown of GOLPH3 and GOLPH3L resulted in 













5.6  Discussion  
In this chapter, we validated the interaction between GOLPH3 and POMGnT1 
as identified in the T7 phage display. Through the utilization of a GST pull down 
assay, we demonstrated that GOLPH3 physically interacted with POMGnT1. It is 
reasonable to speculate that this interaction is direct as the characteristic feature of 
phage display is its ability to identify binary interactions between proteins. However 
we cannot exclude the possibility that these two proteins constitute part of a larger 
multimeric complex. Indeed there have been some speculations that the 
glycosyltransferases implicated in O-mannosylation in particular, POMGnT1, fukutin, 
FKRP and LARGE forms a complex (Kuga et al., 2012). This speculation stems from 
the observations that defects in these genes result in the same loss of α-dystroglycan 
modification (Yoshida-Moriguchi et al., 2010, Kuga et al., 2012). Given the 
significant homology between the two GOLPH3 isoforms (GOLPH3 and GOLPH3L), 
as well as the fact that both proteins demonstrated interactions with the POMGnT1 
peptide in the T7 phage display, we also assessed whether GOLPH3L could pull 
down POMGnT1 from HeLa cells. We provide evidence that the POMGnT1 
interaction is indeed conserved for GOLPH3L suggesting similar roles for the 
GOLPH3 proteins in O-mannosylation. In addition to demonstrating physical 
interaction between the GOLPH3 proteins and POMGnT1, we provide evidence of 
co-localization of the proteins at the Golgi.  
The T7 phage display not only identified a novel interaction between 
GOLPH3 and POMGnT1, but also revealed the domain on POMGnT1 that is 
responsible for mediating interacting with GOLPH3, ie the stem domain. The 
importance of the POMGnT1 stem domain for GOLPH3 binding was confirmed using 
GST pull down analysis. This was based on our observations that substitutions of 
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amino acids within this domain led to the loss of interaction with the GOLPH3 
proteins. Additionally, L
193
 present within the stem domain was identified as a critical 
amino acid important for this interaction as a single base substitution at this position 
resulted in reduced GOLPH3 and GOLPH3L binding. Although the GOLPH3 protein 
is known to exist as a peripheral membrane protein, our result which demonstrates the 
interaction between the stem (lumenal) domain of POMGnT1 and GOLPH3 could 
suggest that the latter may be present in the lumen of the Golgi as well. In support of 
this speculation, one study demonstrated that a small proportion of GOLPH3 does 
exist in the lumen of the Golgi although the majority of GOLPH3 still predominantly 
localized to the Golgi periphery, (Bell et al., 2001). This study specifically utilized 
cryosections of Golgi fractions to allow for maximum availability of potential 
antigenic epitopes to GOLPH3 antibodies (Bell et al., 2001).  In addition, there are 
reports indicating that there could be a pool of GOLPH3 in cells that is not 
peripherally associated with the Golgi. These studies were primarily based on the rat 
homolog of GOLPH3, Gmx33. In one such study, the high salt washes of a rat liver 
Golgi fraction or membrane of cells expressing Gmx33 resulted in 80-90% loss of 
Gmx33 from Golgi membranes. However a small proportion of Gmx33 (10-20%) 
remained on the membrane (Snyder et al., 2006), and thus could represent a pool of 
GOLPH3 that is more tightly associated with the Golgi. In another study, multiple 
detergent extractions of rat liver Golgi demonstrated that Gmx33 distributed to all 
three phases in detergent partitioning experiments (aqueous, detergent soluble and 
detergent insoluble) with the majority of Gmx33 (55%) partitioning into  the detergent 
soluble phase (Wu et al., 2000). The inability of Gmx33 to completely partition to the 
aqueous phase which is typical for peripheral membrane proteins, again suggests the 
presence of a pool of Gmx33 that may not be peripherally associated with the Golgi. 
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In line with the speculation that different Gmx33 populations may exist within cells, a 
2D immunoblot analysis of a rat liver Golgi fraction resulted in the detection of 
several forms of Gmx33 displaying a range of pI of 5.4 to 6.1, representing 
differentially modified forms of the protein (Wu et al., 2000).  
An important finding in this thesis is that the Golgi targeting of POMGnT1 is 
dependent on its interaction with GOLPH3 as amino acid substitutions within the 
stem domain of POMGnT1 or at L
193
 led to the inability of the transferase to localize 
to the Golgi. The role of GOLPH3 in maintaining the Golgi localization of POMGnT1 
is further supported by our observation that the transferase failed to localize to the 
Golgi following RNAi mediated knockdown of endogenous levels of both GOLPH3 
and GOLPH3L. In the yeast system, it is the cytoplasmic tail of mannosyltransferases 
that mediates its interaction with Vps74 which is subsequently required for 
maintaining the localization of the enzymes at the Golgi (Tu et al., 2008; Scott et al., 
2008). With respect to mammalian glycosyltransferases however, there is little 
evidence to clearly support a role for the cytoplasmic tail in maintaining Golgi 
localization (Moreman et al., 2012).  In line with this, we have identified the stem 
domain on POMGnT1 as the important region for mediating its interaction with 
GOLPH3 which subsequently enables POMGnT1 to localize to the Golgi. Indeed 
there have been speculations that the stem region of POMGnT1 may contain a 
targeting signal for the Golgi apparatus (Manya et al., 2003). This is due to the fact 
that mutations in the stem domain of POMGnT1 results in a complete loss of enzyme 
activity (Taniguchi et al., 2003; Vervoort et al., 2004; Biancheri et al., 2006; Hehr et 
al., 2007), which is in striking contrast to other transferases where mutations outside 
the catalytic domain rarely reduces enzyme activity as observed with GnTII (Wang et 
al., 2002) and XGalT-1 (Okajima et al., 1999). Thus the loss of POMGnT1 enzyme 
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activity following mutations in its stem domain could potentially be attributed to its 
inability to localize to the Golgi.  
We speculate that the mislocalization of POMGnT1 oberved following 
GOLPH3 knockdown or disruption of its interaction with GOLPH3 is due to the 
inability of POMGnT1 to be retained in the Golgi, leading to relocation of the 
transferase potentially to the ER. However, to determine the exact location of the 
mislocalized POMGnT1, GOLPH3 depleted cells expressing POMGnT1 will need to 
co-stained with an ER marker. Nevertheless, the failure of POMGnT1 to localize to 
the Golgi in the absence of GOLPH3 suggests that POMGnT1 could exhibit 
compromised enzymatic activity. Thus the next chapter will focus on elucidating the 
biological impact of GOLPH3 knockdown on O-mannosylation, a pathway in which 











CHAPTER 6 ELUCIDATING THE PHYSIOLOGICAL 
FUNCTION OF THE GOLPH3-POMGnT1 
INTERACTION  
6.1       Introduction 
In this chapter, we sought to establish the physiological significance of the 
novel GOLPH3-POMGnT1 interaction. POMGnT1 is involved in O-mannosylation, a 
unique type of glycoyslation which is restricted to a limited group of mammalian 
glycoproteins, specifically those of the brain, nerve and skeletal muscle (Endo T, 
1999). However the best characterized glycoprotein modified by this pathway is α-
dystroglycan, a component of the dystrophin glycoprotein complex (DGC) which is 
found in the sarcolemmma membrane surrounding muscle fibres. The DGC acts to 
physically couple the extracellular matrix that surrounds each myofibre to the 
intracellular actin cytoskeleton (Blake et al., 2002; Henry and Campbell, 1999; 
Durbeej et al., 1998). Thus, the DGC plays a vital role in maintaining skeletal muscle 
integrity (Cote et al., 1999; Cohn et al., 2002). In addition, the DGC mechanically 
protects the sarcolemma against shear stress that is generated during muscle 
contraction (Combs and Ervasti, 2005)  
α-dystroglycan represents a vital component of the DGC as it mediates 
interactions with several ligands present in the extracellular matrix including agrin, 
perlecan, neurexin and most importantly, laminin (Bowe et al., 1994; Campanelli et 
al., 1994; Gee et al., 1994 and Sugiyama et al., 1994). These interactions are critically 
dependant on the glycosylation status of the α-dystroglycan glycoprotein (Michele et 
al., 2002; Michele and Campbell, 2003 and Muntoni et al., 2004). Consequently, 
pertubations in the glycosylation of α-dystroglycan disrupts the vital interaction 
between α-dystroglycan and its ligands and impairs its attachment to the extracellular 
matrix leading to various forms of congenital muscular dystrophies (CMD) 
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(Holzfeind et al., 2002; Michele et al., 2002; Kanagawa et al., 2005). The alteration in 
functional glycosylation of α-dystroglycan is based on observations that the 
glycoprotein displays a loss of immunoreactivity to one or both monoclonal 
antibodies, IIH6 and VIA4-1  (Brockington et al., 2002; Grewal et al., 2002; Hayashi 
et al., 2001; Kano et al., 2002; Michele et al., 2002). The antibodies are specific for 
different glyco-epitopes on α-dystroglycan in which IIH6 recognizes the glycosylated 
laminin binding glycan (Ervasti and Campbell, 1993; Longman et al., 2003) whereas 
VIA4-1 reacts with a currently unidentified glycosylated epitope (Longman et al., 
2003). Here we analysed the impact of GOLPH3 knockdown on the glycosylation of 
α-dystroglycan using the immunoreactivity of the glycoprotein to IIH6 and VIA41 as 
a read-out.  
In this chapter, we also attempted to investigate the potential link between the 
newly identified GOLPH3-POMGnT1 interaction and muscle eye brain disease 
(MEB). Results from this analysis may not only provide clinical significance for our 
work, but also serve to underscore the physiological relevance of the GOLPH3-
POMGnT1 interaction. MEB is an autosomal recessive disorder characterized by 
congenital muscular dystrophy, ocular abnormalities and brain malformation (type II 
lissencephaly) (Santavuori et al., 1989), caused by loss of function mutations in the 
gene encoding POMGnT1 (Yoshida et al., 2001). The majority of the mutations in 
POMGnT1 occur within the catalytic domain of the gene (Hehr et al, 2007), however 
several missense mutations within the stem domain of POMGnT1 have also been 
identified in patients with MEB. The first of these mutations E223K, was identified in 
exon 8 of a 12-year old Japanese male and an 8-year old Belgian female (Taniguchi et 
al., 2003). R265H was identified on exon 9 in a pair of Finnish siblings (Vervoort et 
al., 2004), while C269Y was found on exon 9 in a 7-year old Japanese female 
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(Taniguchi et al., 2003). Each of these patients were compound heterozygotes, 
possessing additional mutations in another allele of POMGnT1 (Taniguchi et al., 
2003, Vervoort et al., 2004).  Interestingly, the single amino acid substitution E223K 
and C269Y were shown to result in a complete loss of enzymatic activity based on in 
vitro assays (Manya et al., 2003). In light of our data which demonstrates that the 
stem domain of POMGnT1 mediates interaction with GOLPH3, we explored the 
possibility that the lack of enzymatic activity of the mutants in diseased individuals 
could be a result of the inability of the transferase to localize to the Golgi due to the 















6.2   Selection of cell lines for assessment of α-dystroglycan glycosylation  
HeLa cells were initially analyzed for its capacity to functionally glycosylate 
α-dystroglycan. Here, FACS analysis was utilized to assess the glycosylation of cell 
surface α-dystroglycan using IIH6 immunoreactivity as a read-out. Briefly, HeLa cells 
in culture were detached using enzyme free dissociation buffer followed by 
incubation with the IIH6 monoclonal antibody and a fluorescently labelled secondary 
antibody. Our results however showed that IIH6 failed to bind cell surface α-
dystroglycan as demonstrated by the lack of shift in the FACS profile compared to the 
negative control (Figure 6.1a). This result suggested that HeLa cells are unable to 







Figure 6.1a Assessing the glycosylation of cell surface α-dystroglycan in HeLa 
Cells in culture were detached with enzyme free dissociation buffer 
followed by FACS analysis with the IIH6 antibody. NC: Negative 
control (NC) without the primary antibody is shown as grey trace. Cell 
surface α-dystroglycan in HeLa cells failed to display 




To confirm this, we assessed the immunoreactivity of IIH6 to recombinant α-
dystroglycan. α-dystroglycan was fused to an Fc tag and expressed in HeLa cells. In 
its natural state, α-dystroglycan exists as a cell surface membrane protein as it is 
physically linked to the transmembrane protein, β-dystroglycan (Ervasti and 
Campbell, 1991). However, the omission of β-dystroglycan from our fusion construct 
allowed for the secretion of the α-dystroglycan glycoprotein into the cell culture 
medium. 48 hours after tranfection, the recombinant protein was harvested from the 
media, resolved on SDS-PAGE and subjected to Western blotting. We found that 
HeLa cells expressed the α-dystroglycan protein as demonstrated by the ~ 120 KDa 
size band observed on the western blot using anti-Fc antibodies (Figure 6.1b). 
However, this cell line was unable to functionally glycosylate α-dystroglycan due to 
the lack of a signal with the IIH6 monoclonal antibody (data not shown). Taken 
together these data suggest that HeLa cells were not capable of functionally 
glycosylating α-dystroglycan and thus did not represent a suitable cell line for this 
section in our work. Since the glycoyslation of α-dystroglycan is regulated in a cell-
specific manner (Ibraghimov-Beskrovnaya et al., 1992; Durbeej et al., 1998; Henry 
and Campbell, 1999), it is likely that the carbohydrate epitope which is recognized by 



















Figure 6.1b   Assessing the glycosylation of recombinant α-dystroglycan in HeLa 
Fc tagged α-dystroglycan secreted into the culture medium by HeLa 
cells was harvested and resolved on SDS-PAGE gel followed by 
Western blotting with anti-Fc antibody. A band of ~120kDa 
representing α-dystroglycan was observed.  
 
We subsequently assessed HEK293 cells for their capacity to functionally 
glycosylate α-dystroglycan. Through the use of FACS analysis we demonstrate that 
cell surface α-dystroglycan in HEK293 cells displayed immunoreactivity to IIH6 as 
seen by the significant shift in the FACS profile compared to the negative control 
(Figure 6.2a). This positive interaction with IIH6 was confirmed using the Fc tagged 
α-dystroglycan recombinant protein. Our results showed that HEK293 cells expressed 
and functionally glycosylated α-dystroglycan as seen in the Western blots using anti-
Fc and IIH6 antibodies respectively (Figure 6.2b).  However, the signal observed on 
the IIH6 blot was of weak intensity, which led us to the conclusion that the FACS 
approach with the IIH6 monoclonal antibody represented a more sensitive assay for 
examining the glycosylation status of α-dystroglycan and thus was utilized in 
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subsequent assays. Nonetheless, these results are reflective of the functional 
glycosylation status of α-dystroglycan produced in HEK293 cells. We subsequently 
utilized HEK293 cells to assess the impact of GOLPH3 knockdown on α-
dystroglycan glycosylation. We also examined the ability of cell surface α-
dystroglycan to bind VIA4-1. Our results showed that the VIA4-1 monocloanl 
antibody displayed immunoreactivity to cell surface α-dystroglycan albeit weakly as 
observed by the marginal shift in the FACS profile in comparison to the negative 











Figure 6.2a Examining the IIH6 immunoreactivity of cell surface α-
dystroglycan in HEK293 
Cells in culture were detached with enzyme free dissociation buffer 
and incubated with the IIH6 antibody (red trace). NC: Negative control 
(NC) without the primary antibody is shown as grey trace. Cell surface 


















Figure 6.2b  Examining the IIH6 immunoreactivity of recombinant α-
dystroglycan in HEK293 
Fc tagged α-dystroglycan secreted into the culture medium by HEK293 
cells was harvested and resolved on SDS-PAGE gel followed by 
Western blotting. α-dystroglycan (~120kDa) was observed with anti-Fc 











Figure 6.2c  Examining the VIA4-1 immunoreactivity of cell surface α-
dystroglycan in HEK293 
Cells in culture were detached with enzyme free dissociation buffer 
followed by FACS analysis with VIA41 antibody (red trace). Negative 
control (NC) without the primary antibody is shown as grey trace. 
HEK 293 cell surface α-dystroglycan displayed weak immunoreactvity 
to VIA41.  
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6.3  Evaluating the impact of GOLPH3 knockdown on IIH6 immunoreactivity  
RNAi based interference was employed to reduce endogenous levels of the 
GOLPH3 and GOLPH3L proteins followed by the assessment of the functional 
glycosylation status of cell-surface α-dystroglycan, based on the immunoreactivity of 
the glycoprotein to the IIH6 monoclonal antibody. The FACS analysis was performed 
48 hrs after siRNA treatment which is similar to the timepoint used in 
immunofluorescence study to assess the localization of POMGnT1 following 
GOLPH3/L knockdown (see Figure 5.8).  siRNA targeting POMGnT1 was included 
in our study as a positive control and cells treated with this siRNA clearly 
demonstrated a reduction in IIH6 immunoreactivity in comparison to cells treated 
with the non-targeting siRNA control (ctrl siRNA) (Figure 6.3a). To knockdown 
endogenous levels of the GOLPH3 proteins, siRNA targeting both GOLPH3 and 
GOLPH3L was co-transfected into HeLa cells. In this study, we utilized the same 
GOLPH3 siRNA that was used in the immunofluorescence assay to assess the 
localization of POMGnT1 following GOLPH3/L knockdown (see section 5.5). Our 
results showed that the knockdown of GOLPH3 and GOLPH3L resulted in a 
reduction in IIH6 immunoreactivity when compared with cells transfected with the 
control siRNA (Figure 6.3b). This result is indicative of alterations in the normal 
glycosylation of α-dystroglycan. A further comparison of the effects of POMGnT1 
and the GOLPH3/L knockdown on IIH6 immunoreactivity is illustrated in Figure 
6.3c. Figure 6.3c shows that the knockdown of POMGnT1 resulted in a greater loss of 













Figure 6.3a  Evaluating the effects of POMGnT1 knockdown on IIH6 
immunoreactivity  
 HEK293 cells were transfected with POMGnT1 siRNA followed by 
FACS analysis with IIH6 antibody. Ctrl siRNA: non-targeting siRNA 
control. NC: negative control without the primary antibody. RNAi 









Figure 6.3b   Evaluating the effects of GOLPH3 and GOLPH3L knockdown on 
IIH6 immunoreactivity  
 HEK293 cells were co-transfected with GOLPH3 and GOLPH3L 
siRNA followed by FACS analysis with IIH6 antibody. Ctrl siRNA: 
non-targeting siRNA control. NC: negative control without the primary 
antibody.  RNAi mediated knockdown of GOLPH3 and GOLPH3L 










Figure 6.3c  Comparing the impact of POMGnT1 and GOLPH3/L knockdown 
on α-dystroglycan glycosylation 
A comparison of HEK293 cells treated with siRNA targeting 
POMGnT1 or GOLPH3/L siRNAs was carried out. The knockdown of 
POMGnT1 resulted in greater loss of IIH6 immunoreactivity compared 
to the double knockdown of GOLPH3 and GOLPH3L.  
 
The knockdown efficieny of POMGnT1, GOLPH3 and GOLPH3L following 
RNAi mediated silencing was assessed at the mRNA level using qRT-PCR. Total 
RNA was extracted from cells 48 hours after transfection with the corresponding 
siRNA. Following the conversion to cDNA, qRT-PCR analysis was performed. The 
results show that the POMGnT1 and GOLPH3 siRNA resulted in approximately 80% 
knockdown of POMGnT1 and GOLPH3 mRNA levels respectively (Figure 6.4a and 
b), while the  GOLPH3L siRNA resulted in greater than 90% reduction in GOLPH3L 
mRNA levels (Figure 6.4c). The analysis was performed in triplicates and was 
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Figure 6.4 Assessment of RNAi efficiency at the mRNA level 
The relative POMGnT1, GOLPH3 and GOLPH3L mRNA expression 
levels following transfection with the corresponding siRNAs were 
quantified by qRT-PCR. Bar charts summarize data obtained from three 
replicates. Error bar indicates standard error/deviation. A significant 








6.4  Evaluating the impact of GOLPH3 knockdown on VIA4-1 
immunoreactivity  
In this section, the VIA4-1 monoclonal antibody was utilized to examine the 
glycosylation status of α-dystroglycan following the knockdown of GOLPH3 and 
GOLPH3L. Through a similar use of FACS analysis, our results demonstrated that the 
knockdown of POMGnT1 led to a slight reduction in VIA4-1 immunoreactivity 
(Figure 6.5a) when compared to cells transfected with the control siRNA. This is in 
striking contrast to the significant impact the knockdown of POMGnT1 had on IIH6 
immunoreactivity (Figure 6.3a). However we attribute this marginal effect to the poor 
binding capabilities of the VIA4-1 monoclonal antibody to cell surface α-
dystroglycan in HEK293 cells as shown in Figure 6.2c. As a consequence, we failed 
to detect any alterations in VIA4-1 immunoreactivity following the knockdown of the 











Figure 6.5a  Evaluating the effects of POMGnT1 knockdown on VIA4-1 
immunoreactivity  
HEK293 cells were transfected with POMGnT1 siRNA followed by 
FACS analysis with VIA4-1 antibody. Ctrl siRNA: non-targeting 
siRNA control. NC: negative control without the primary antibody.  
Cell surface α-dystroglycan in cells treated with POMGnT1 siRNA 














Figure 6.5b   Evaluating the effects of GOLPH3 and GOLPH3L knockdown on 
VIA4-1 immunoreactivity  
 HEK293 cells were co-transfected with GOLPH3 and GOLPH3L 
siRNA followed by FACS analysis with VIA4-1 antibody. Ctrl siRNA: 
non-targeting siRNA control. NC: negative control without the primary 
antibody. Cell surface α-dystroglycan in cells treated with GOLPH3 
and GOLPH3L siRNAs failed to demonstrate reduction in VIA4-1 
immunoreactivity. 
 
6.5 Investigating the link between GOLPH3 and the development of MEB 
6.5.1 Generation of POMGnT1 mutants present in MEB 
The amino acid substitutions, E223K, R265H and C269Y on POMGnT1 were 
generated to replicate mutations present in patients with MEB. Interstingly, these 
mutations (highlighted in blue in Figure 6.6) is in close proximity to the to the 
GOLPH3 interaction region on POMGnT1 (highlighted in red in Figure 6.6) as 
identified in the T7 phage display. The substitutions were performed by introducing 
point mutations at specific nucleotides (see Table 6.1) using the QuikChange II XL 
site directed mutagenesis kit. The POMGnT1 mutants were then fused to a His tag 
and transfected into HeLa cells to assess for interactions with GOLPH3 through the 
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utilization of GST-pull down assays. The mutants were also fused to a HA tag to 
allow for the assessment of their subcellular distribution as visualized by 
immunoflourescence. We focused our efforts on assessing mutants that exist within 
the stem domain of POMGnT1 and represented missense mutations in MEB patients. 
Mutations in the POMGnT1 stem domain that resulted in premature protein 
truncations were not included in our study as such mutations would cause major 
perturbations to the protein structure and subsequently confound any data from the 




Figure 6.6 Positions of POMGnT1 mutations in MEB patients relative to the 
GOLPH3 interacting region 
Three missense mutations in POMGnT1 that exist in patients with MEB 






Table 6.1 Generation of POMGnT1 mutants that exist in MEB patients 
Three missense mutations in POMGnT1 that exist in patients with MEB 
were constructed via site-directed mutagenesis. Single point mutations 





6.5.2 Assessment of interactions between GOLPH3 and POMGnT1 mutants    
existing in MEB patients 
GST pull down assays were performed to analyze the binding interaction 
between GOLPH3 and E223K, R265H and C269Y. Briefly, lysates of HeLa cells 
expressing the various POMGnT1 mutants was incubated with purified GST 
GOLPH3. The precipitates were then probed with anti-His antibodies to detect for the 
presence of POMGnT1. As seen in Figure 6.7, GST-GOLPH3 demonstrated reduced 
binding to E223K, R265H and C269Y when compared to the binding of GOLPH3 to 
wild type POMGnT1 protein (WT). As indicated in the lower panel (input), equal 









Figure 6.7 Assessment of interactions between GOLPH3 and POMGnT1 
mutations present in MEB 
Lysates of HeLa cells expressing POMGnT1 E223K, R265H, or 
C269Y were incubated with purified GST GOLPH3. Precipitates were 
probed with anti-His antibodies to detect for the presence of 
POMGnT1. GST-GOLPH3 demonstrated reduced binding to the three 
missense mutations in POMGnT1. 
 
6.5.3   Localization analyses of POMGnT1 mutants existing in MEB patients 
Immunofluorescence assays were carried out to assess the subcellular 
distribution of the E223K, R265H and C269Y. In this assay, the cells were co-stained 
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with anti-HA and anti-giantin 48 hours after transfection with the individual 
constructs. As depicted in the Figure 6.8, E223K, R265H and C269Y failed to 
localize to the Golgi shown by the inability of the proteins to co-localize with the 
Golgi marker, giantin. The localization of the wild type POMGnT1 is shown in the 
top panel for comparisons. The localization data of the POMGnT1 mutants correlated 
well with that of the GOLPH3 interaction study as mutants which failed to localize to 










Figure 6.8  Subcellular localization of POMGnT1 mutants present in MEB  
HeLa cells expressing the HA tagged POMGnT1 mutant constructs 
were fixed and stained with anti-HA (green) and anti-giantin (red) 
specific antibodies. Nuclei were counterstained with DAPI (blue). 





6.6  Discussion  
To investigate the biological significance of the novel GOLPH3-POMGnT1 
interaction identified in this study, RNAi based interference was utilized to reduce 
endogenous levels of GOLPH3 and GOLPH3L proteins followed by the assessment 
of the functional glycosylation status of cell-surface α-dystroglycan. This was based 
on immunoreactivity of α-dystroglycan to the IIH6 monoclonal antibody which 
recognizes the laminin binding glyco-epitope on the glycoprotein (Ervasti and 
Campell, 1993). We show that the RNAi mediated knockdown of POMGnT1 resulted 
in the disruption of α-dystroglycan glycosylation, reflected by the reduction in 
immunoreactivity to IIH6. A complete loss of IIH6 immunoreactivity following the 
knockdown of POMGnT1 was not observed in our assays. We speculate that this may 
be attributed to the 20% of POMGnT1 mRNA levels remaining following siRNA 
treatment as observed in the RT-PCR analysis and thus is indicative of residual 
POMGnT1 activity. Another reason for the inability to observe a complete loss in 
IIH6 immunoreactivity could be due to the fact that defects in POMGnT1 are known 
to partially inhibit the formation of the laminin binding glycan (Yoshida-Moriguchi  
et al., 2010), the details of which will be described below. Importantly, we show that 
the RNAi mediated knockdown of GOLPH3 and GOLPH3L resulted in a reduction in 
IIH6 immunoreactivity which is indicative of alterations in the normal glycosylation 
of α-dystroglycan. The inability to observe a greater loss of IIH6 immunoreactvity can 
again be attributed to the residual levels of the GOLPH3 and GOLPH3L mRNA 
remaining after siRNA treatment. Although the RNAi mediated targeting of 
GOLPH3L led to significant reductions in mRNA levels (>90%), GOLPH3L is 
known to be under-expressed in mammalian cells (Nakashima-Kamimura et al., 
2005). Thus it would be more important to attain greater knockdown efficiency of 
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GOLPH3 in order to observe dramatic effects on IIH6 immunoreactivity. 
Nevertheless, these results suggest a novel role for the GOLPH3 proteins in 
glycosylation of α-dystroglycan. 
Recent studies has demonstrated that the glycan on α-dystroglycan responsible 
for laminin binding is a novel phosphorylated O-mannosyl glycan consisting of a 
phosphate molecule attached to the 6-hydroxyl residue of the initiating mannose 
(Yoshida-Moriguchi et al., 2010) and is further extended with repeating units of [-3-
xylose-α1, 3-glucoronic acid-β1-] (Inamori et al., 2012) as illustrated in Figure 1.8. 
Although POMGnT1 is not known to be involved in direct modification of this post-
phosphoryl structure, the GlcNAc-β1,2-branch formed by POMGnT1 is  thought to 
facilitate the formation of this structure by creating favourable circumstances (Kuga et 
al., 2012). This conclusion was based on the observation that defects in POMGnT1 
partially inhibited the postphosphoryl modification of this glycan (Yoshida-Moriguchi 
et al., 2010). Yoshida-Moriguchi et al demonstrated that the majority of α-
dystroglycan isolated from skeletal muscles of POMGnT1 knockout mice exhibited 
binding to IMAC beads, which is known to interact only with monoester-linked 
phosphorylated compounds (Yoshida-Moriguchi et al., 2010). This result suggests 
that the monoester-linked residues on α-dystroglycan isolated from POMGnT1 
knockout mice are incapable of further modification and thus lacks the post-
phosphoryl moiety required for laminin binding (Kuga et al., 2012). Based on the 
negative impact of downregulated GOLPH3 and POMGnT1 on IIH6 
immunoreactivity, it is tempting to speculate that GOLPH3 influences the formation 
of the novel phosphorylated O-mannosyl glycan, at least partially via mediating 
POMGnT1 localization. We aim to further characterize the glycans that exists on α-
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dystroglycan following the reduction in GOLPH3 and GOLPH3L levels by 
employing advanced analytical methods as discussed in section 7.2.2.  
In our studies, we failed to observe a reduction in VIA4-1 immunoreactivity to 
α-dystroglycan following the RNAi mediated knockdown of GOLPH3 and 
GOLPH3L. However, we attribute this to the poor binding capabilities of the VIA4-1 
antibody to cell surface α-dystroglyan. Thus alternative sources of the antibody will 
be required to ascertain the impact of GOLPH3 knockdown on VIA4-1 
immunoreactivity. Nonetheless, studies have demonstrated that the IIH6 antibody but 
not VIA4-1, blocks laminin binding which suggests that IIH6 and laminin recognize 
similar glyco-epitopes on α-dystroglycan (Matsumura et al., 1997, Brown et al., 
1999). Thus it is reasonable to speculate that the observed reduction of IIH6 
immunoreactivity following GOLPH3/L knockdown signifies a concomitant 
reduction in laminin binding capabilities. This result suggests that the GOLPH3 
proteins have the potential to affect the ligand binding capabilities of α-dystroglycan, 
raising the possibility that GOLPH3 could be implicated in MEB. This potential link 
was further investigated in our study.  
Several missense mutations within the stem domain of POMGnT1 have been 
identified in patients with MEB. They are represented by E223K (Taniguchi et al., 
2003), R265H (Vervoort et al., 2004) and C269Y (Taniguchi et al., 2003). Based on 
in vitro assays, E223K and C269Y were shown to result in a complete loss of 
enzymatic activity (Manya et al., 2003). Although not examined, it is likely that 
R265H would also display a lack of enzymatic activity since all POMGnT1 mutations 
analyzed to date have demonstrated abolished enzyme activity (Hehr et al,. 2007). 
POMGnT1 is considered to be a unique glycosyltransferase as missense mutations 
within its stem domain leads to a loss in enzymatic activity (Manya et al., 2003). This 
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is in contrast to other transferases where missense mutations outside the catalytic 
domain rarely affect enzymatic activity (Akasaka-Manya et al., 2004). To date, 
missense mutations that result in the development of human genetic disorders, are all 
found within the catalytic domain of glycosyltransferases. For instance, congenital 
disorder of glycosylation type IIa (CGD-IIa) is caused by four missense mutations 
that lie within the catalytic domain of GnT-II (Wang et al,. 2002).  Progeroid type 
Ehlers-Danlos syndrome occurs as a result of two misssense mutations within the 
caytalytic domain of galactosyltransferase-1 (X-GalT-1) (Okajima et al., 1999).  
Interestingly, E223K, R265H and C269Y lie within close proximity to the 
GOLPH3 interaction region that was identified in the T7 phage display.  Here, we 
explored the possibility that the lack of enzymatic activity of these POMGnT1 
mutants could be a result of the inability of the transferase to localize to the Golgi due 
to the loss of GOLPH3 interaction. In line with our speculation, we show that the 
POMGnT1 mutants, E223K, R265H and C269Y demonstrated reduced interactions 
with GOLPH3. We propose that the GOLPH3 interaction interface may extend 
beyond the residues identified in the T7 phage display to these additional amino acids 
within the POMGnT1 stem region. In addition to demonstrating the reduction in 
GOLPH3 binding capabilities of POMGnT1, we also show that the mutants failed to 
localize to Golgi. This was demonstrated by the inability of E223K, R265H and 
C269Y to co-localize with the Golgi marker Giantin. Taken together our results 
suggest that the loss of enzymatic activity of mutations within the stem domain of 
POMGnT1 may be attributed to their reduction in interaction capabilities with 
GOLPH3, subsequently leading to the failure of the transferases to be retained in the 
Golgi. This could potentially represent one of the molecular mechanisms leading to 
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the development of MEB. The results also further underscore the physiological 




















CHAPTER 7 CONCLUSIONS AND RECOMMENDATIONS 
7.1  Conclusions 
The main aims of this thesis were to gain a further understanding into the role 
of GOLPH3 in mammalian glycosylation through identification of novel interacting 
partners and to determine the physiological significance of the novel interaction in a 
biological system.  We hypothesized that GOLPH3 plays a similar role as its yeast 
counterpart Vps74p, in which the latter is implicated in controlling the steady state 
distribution of specific mannosyltransferases at the yeast Golgi. The basis of this 
speculation stems from the fact that GOLPH3 represents a highly conserved protein 
found across the entire eukaryotic lineage (Wu et al, 2000). In addition, GOLPH3 and 
GOLPH3L corrected for phenotypic defects seen in vps74 deleted yeast cells (Tu et 
al., 2008).  
Here we employed the use of a T7 phage display as a screening platform to 
identify novel interacting partners of GOLPH3 and GOLPH3L. This led to the 
previously unidentified interaction between the GOLPH3 proteins and POMGnT1. 
The identification of this interaction was compelling as POMGnT1 is involved in O-
linked mannosylation which is known to be a yeast type modification (Nakajima-
Ballou, 1974; Raizada et al., 1975; Hayette et al., 1992; Herscovics and Orlean, 
1993). This result highlights the conserved role of GOLPH3 family of proteins in 
mediating yeast type modificatios. In the same screen, alongside POMGnT1, we also 
identified other glycosyltransferases that are implicated in the initiation of mammalian 
O-linked glycosylation. This finding correlates well with a recent finding by Ali et al, 
who demonstrated that GOLPH3 is indeed involved in O-glycosylation as it interacts 
with C2GnT1.  
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To further validate this finding, we showed that GOLPH3 and GOLPH3L 
pulled down POMGnT1 from cells thus providing evidence for physical interaction 
between the proteins. In addition to interaction data, we demonstrated that GOLPH3 
and GOLPH3L co-localized with POMGnT1 at the Golgi. In line with the result from 
the T7 phage display, we confirmed that the stem domain on POMGnT1 is critical for 
mediating interactions with GOLPH3, as substitutions within this domain led to loss 
of binding to GOLPH3 and GOLPH3L. Importantly we showed that the Golgi 
targeting of POMGnT1 is dependent on its interaction with GOLPH3. This is 
reflected by our results demonstrating that amino acid substitutions within the 
GOLPH3 binidng region on POMGnT1 led to the inability of the transferase to 
localize to the Golgi. This finding is consistent with previous speculation that the stem 
region of POMGnT1 may contain a targeting signal for the Golgi apparatus (Manya et 
al., 2003). The role of GOLPH3 in maintaining the Golgi localization of POMGnT1 is 
further supported by our observation that the transferase failed to localize to the Golgi 
following RNAi mediated knockdown of endogenous levels of GOLPH3 and 
GOLPH3L.  
To determine the physiological relevance of the newly identified GOLPH3-
POMGnT1 interaction, we assessed the impact of reduced GOLPH3/L levels on the 
glycosylation status of α-dystroglycan. This was based on the immunoreactivity of the 
glycoprotein to the IIH6 monoclonal antibody which accurately reflects its laminin 
binding status, as both recognize similar glyco-epitope on α-dystroglycan (Ervasti and 
Campbell, 1993). As a positive control, we showed that the RNAi mediated 
knockdown of POMGnT1 resulted in reduced IIH6 immunoreactivity. Importantly, 
the RNAi mediated knockdown of GOLPH3 and GOLPH3L also resulted in a 
reduction in IIH6 immunoreactivity which is reflective of the disruption of the normal 
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glycoyslation of α-dystroglycan. These results indicate a novel role for the GOLPH3 
proteins in glycosylation of α-dystroglycan.  
To further underscore the physiological relevance of the GOLPH3 and 
POMGnT1 interaction, we assessed the GOLPH3 interaction capabilities and 
subcellular localization of POMGnT1 mutants that were previously described in 
patients with MEB. These mutants represent missense mutations occurring in the stem 
domain of POMGnT1. We discovered that three of these mutations demonstrated 
reduced interactions with GOLPH3 and in addition, failed to localize to the Golgi. 
These findings reveal a novel role for GOLPH3 and GOLPH3L in mediating 
interactions with POMGnT1 and maintaining its Golgi localization. Loss of this 
interaction could underlie one of the molecular mechanisms leading to the 
development of MEB.   
 7.2  Recommendations for future research 
Based on the thesis findings the following recommendations have been 
suggested for future research under these sections.  
7.2.1   Assesment of the ability of GOLPH3 to localize to the lumen of the Golgi 
 Our result demonstrates that GOLPH3 interacts with the stem (lumenal) 
domain on POMGnT1, suggesting that GOLPH3 may be present in the lumen of the 
Golgi. To demonstrate this, we aim to utilize live-cell imaging by using a yellow 
fluorescent protein (YFP)-based bimolecular fluorescence complementation (BiFC) 
assay, which requires association of query proteins fused to individual fragments of 
YFP to elicit fluorescence (Hu et al., 2002). A lumenal reporter molecule consisting 
of an N-terminal portion of YFP fused to the C-terminus of POMGnT1 (amino acids 
1-300) will be engineered. In turn, the C-terminal portion of YFP will be fused to the 
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N-terminus of the GOLPH3 proteins. Following the tranfection of the constructs into 
HeLa cells, the ability of GOLPH3 to localize to the lumen of the Golgi will be 
reflected as a fluorescent signal following reconstitution of the YFP protein when 
both proteins are within the same subcellular compartment. By contrast, no BiFc 
signal should be observed in control cells expressing C-YFP and an appropriately 
tagged ER reporter protein for example POMT1. This experiment will allow us to 
conclusively demonstrate that GOLPH3 can indeed localize to the lumen of the Golgi 
as suggested by results from our study.  
7.2.2 Assessement of enzymatic activity of POMGnT1 following the disruption 
of its interaction with GOLPH3 
In our work, we have demonstrated that substitutions within the stem domain 
on POMGnT1 (POMGnT19A and POMGnT1 L193A; see Chapter 5) led to the loss 
of GOLPH3 and GOLPH3L interactions as well as the loss of Golgi localization of 
the transferase. The latter is suggestive of the fact that the enzymatic activity of 
POMGnT1 is impaired following disruption of its interaction with GOLPH3 and 
GOLPH3L. However, the activity of these POMGnT1 mutants was not directly 
assessd in our experiments. The current established assay for the measurement of 
POMGnT1 activity as described in Takahashi et al, is based on the amount of 
[
3
H]GlcNAc that is transferred from UDP-GlcNAc onto a synthetic mannosyl 
octapeptide that corresponds to specific amino acids on α-dystroglycan. Briefly, UDP-
[
3
H]GlcNac, mannosylpeptide, and an enzyme source (microsomal membrane 
fraction) is incubated in POMGnT1 reaction buffer [140mM Mes buffer (pH 7.0) 
10mM MnCl2, 2% triton X-100, 5mM AMP and 10% glycerol]. Following 
inactivation, the mixture was subjected to reverse phase high performance liquid 
chromatography. The peptide separation was monitored at 214nm and the 
radioactivity of each fraction was measured.  
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 To assess the impact of loss of GOLPH3 and GOLPH3L interaction on 
POMGnT1 activity, we aim to transiently transfect HeLa cells with the previously 
generated POMGnT1 mutant constructs, POMGnT1 9A and POMGnT1 L193A. The 
microsomal membrane fraction will then be harvested 48 hours after transfection and 
the activity of POMGnT1 in this sample will be measured as indicated above. The 
POMGnT1 activity in the cells transfecetd with the POMGnT mutant constructs will 
be compared to that in cells transfected with the wild type POMGnT1 construct. 
Results from this analysis will provide conclusive evidence that POMGnT1 acivity is 
indeed impaired following the disruption of interaction with the GOLPH3 proteins.   
7.2.3 Glycan analysis of α-dystroglycan following the RNAi mediated 
knockdown of GOLPH3 and GOLPH3L 
An important finding in this thesis is the reduction in functional glycosylation 
of α-dystroglycan following RNAi mediated knockdown of the GOLPH3 proteins. 
However, the exact glycan structures that are affected are not defined at this point. 
Thus, we aim to further characterize these glycans using advanced analytical methods. 
Here, HEK293 cells will be serially transfected with siRNA targeting the GOLPH3 
proteins followed by an Fc tagged α-dystroglycan fusion construct. The secreted 
protein will then be purified using Protein A affinity chromatography. O-linked 
glycans will be released from the purified α-dystroglycan by β-elimination, 
permethylated and subjected to nanospray ionization-MS/MS. The structures of O-
glycans present in these samples will be determined based on the MS/MS 
fragmentation profile. The relative abundance of specific glycan structures from cells 
transfected with GOLPH3 and GOLPH3L siRNAs will be compared to that in cells 
transfected with the control siRNA.   
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A predominant structure found on α-dystroglycan is the O-mannosyl 
tetrasaccharide NeuAcα2-3Galβ1-4GlcNAcβ1-2Man-Ser/Thr. A recent glycomic 
analysis performed on α-dystroglycan isolated from rabbit skeletal muscle 
demonstrated that in addition to this dominant structure, slight variations of this 
tetrasaccharide also exist albeit in lower abundance (Stalnaker et al., 2010) (Figure 
1.7). As POMGnT1 plays a critical role in the formation of these glycans, we 
hypothesize that the tetrasaccharide and its variants will be altered following the 
reduction in GOLPH3 protein levels. Analysis of these glycan structures will provide 
conclusive evidence that GOLPH3 indeed affects the glycosylation of α-dystroglycan. 
Recent studies however, have demonstrated that the critical glycan required for 
laminin binding is a novel phopshorylated O-mannosyl glycan where a phosphate 
molecule is linked to the 6-hydroxyl position of the core O-Man residue on α-
dystroglycan (Yoshida-Moriguchi et al., 2010) and  is further extended with repeating 
units of [-3-xylose-α1,3-glucoronic acid-β1-] (Inamori et al., 2012). Although 
POMGnT1 is not known to be directly involved in the modification of this 
phosphorylated structure, POMGnT1 deficient cells or tissues was shown to partially 
inhibit the formation of the phosphorylated O-mannosyl glycan (Yoshida-Moriguchi 
et al., 2010; Kuga et al., 2012). In light of our evidence that IIH6 immunoreactivity is 
reduced following GOLPH3/L knockdown, it is reasonable to speculate that the 
phosphorylated glycan structure is affected. This structure will be of critical interest in 
our glycan analysis.   
Our analysis will not only be restricted to the O-mannosyl glycans but will 
include studies on the other O-linked glycan structures as well. In addition to the O-
mannosyl tetrasaccharide, another dominant O-glycan structures found in the mucin 
like domain of α-dystroglycan consists of the core-1 type structures (Galβ1-
107 
 
3GalNAcα-O-Ser/Thr). The study by Stalnaker et al once again demonstrated that 
variations of this glycan structure also exist although at lower levels. We hypothesize 
that the O-GalNAc initiated structures may be altered following the reduction of 
GOLPH3 levels. The basis for this speculation stems from results of our T7 phage 
display data which highlights a potential interaction between GOLPH3 and specific 
GalNAc-Ts. Thus the core-1 type structures and its variants will also be assessed in 
the glycan analysis.  
7.2.4   Generation of a GOLPH3 knockout mouse model 
Our results have shown that downregulation of GOLPH3 and GOLPH3L 
affects the functional glycosylation of α-dystroglycan, a component of the dystrophin 
glycoprotein complex (DGC) found in the sarcolemmma of muscle fibres. In addition, 
our results also raise the possibility that GOLPH3-POMGnT1 interaction could be 
implicated in the development of MEB as single point mutations within POMGnT1 
found in patients with MEB demonstrated a loss of GOLPH3 interaction. To further 
substantiate these data and to provide conclusive evidence that could link GOLPH3 to 
MEB, it will be necessary to inactivate the GOLPH3 and GOLPH3 genes in a mouse 
model. Considering the fact that the knockout of GOLPH3 in Drosophila 
melanogaster is lethal, it would not be feasible to generate a complete knockout of 
GOLPH3 in mice. Thus we would attempt to generate a novel knockout mouse that 
has GOLPH3 and GOLPH3L depleted specifically from skeletal muscle using the 
Cre/lox system. GOLPH3 and GOLPH3L will be disrupted in vivo by transgenic 
expression of cre-recombinase from the muscle creatinine kinase promoter.To 
knockout GOLPH3 in mice, we propose that exon 1 of the GOLPH3 gene should be 
targeted for inactivation. This is to ensure the knockdown of the GOLPH3 variant 
(GOLPH3V) which is known to exists at high levels specifically in the skeletal 
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muscles of mice (Nagano-Ito et al, 2007). The GOLPH3V encodes 81 amino acids 
corresponding to exon 1 of the full length GOLPH3 protein (Nagano-Ito et al., 2007).  
The IIH6 and VIA4-1 monoclonal antibodies will be used to confirm the 
reduction of α-dystroglycan in the GOLPH3/L knockout mice. Here, skeletal muscle 
tissue extract will be prepared from wild type (+/+) mice and mutant mice (-/-), 
following which α-dystroglycan will be purified using wheat germ agglutinin (WGA) 
-affinity chromatography.  The glycoproteins will be resolved on SDS-PAGE and 
subjected to western blotting with the two antibodies. To further determine if the 
WGA-enriched glycoproteins isolated from the knockout mice binds to laminin, 
ligand overlay assays will be performed according to Michele et al., 2002. Briefly, 
following the transfer of proteins onto a PVDF membrane, the membrane will be 
equilibrated in laminin binding buffer for 1 hour followed by an overnight incubation 
with the laminin-1 protein. The bound laminin will then be detected using an anti-
laminin antibody.   
The phenotype of the GOLPH3 and GOLPH3L double knockout mice will 
then be assessed by performing rigorous histological analysis. In light of our data 
which shows that the GOLPH3 proteins regulate α-dystroglycan by mediating the 
Golgi localization of POMGnT1, we speculate that the GOLPH3/L mutant mice will 
display phenotypic similarities to that of the POMGnT1 knockout mice. A genetic 
model for POMGnT1 was generated and fully characterized in Liu et al., 2006. In this 
study, leg and tongue muscles from POMGnT1 mutant mice were subjected to 
histological analysis, leading to the identification of dystrophic changes specifically in 
the adult mutant mice skeletal muscle (Liu et al., 2006). In addition, severe 
phenotypes were observed in the brain and eye in these mice (Liu et al., 2006). The 
multiple developmental effects observed in the POMGnT1 mutant mice is clinically 
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similar that observed in patients with MEB (Liu et al., 2006). Thus the histological 
examination of skeletal muscle, brain and the eye will be of high importance during 
the characterization of the GOLPH3/L knockout mice. Results from this study will 
not only complement data obtained in this thesis but could establish a definite link 
between GOLPH3 and MEB.  
7.2.5  Elucidating the impact of GOLPH3 on RPTPζ/phosphacan glycoyslation 
Receptor protein tyrosine phosphatase ζ (RPTPζ) and its secreted variant 
phosphacan is primarily expressed in the central nervous system (CNS) (Shitara et al., 
1994; Maeda et al., 1995) and is known to play vital roles in key developmental 
neural processes (Ida et al., 1996; Soh et al., 2007). RPTPζ/phosphacan was recently 
identified as a substrate for O-mannosyl glycosylation (Dwyer et al., 2012). In 
addition, it was demonstrated that the normal glycosylation of RPTPζ/phosphacan is 
disrupted in the brain of animal models of MEB lacking functional POMGnT1. 
RPTPζ/phosphacan isolated from POMGnT1 knockout models demonstrated 
reductions in molecular weight of the glycoprotein and a loss of interaction with the 
the characteristic Human Natural Killer-1 (HNK-1) carbohydrate epitope (Dwyer et 
al., 2012). POMGnT1 knockout mice exhibited abnormalities in myelination (Harroch 
et al., 2000, 2002) and impaired learning and memory (Niisato et al., 2005). These 
phenotypes albeit mild raises the possibility that abnormal glycosylation of 
RPTPζ/phosphacan may contribute to the pathogenesis of MEB (Dwyer et al., 2012). 
Given the dramatic effect that POMGnT1 has on the glycosylation of 
RPTPζ/phosphacan, we aim to examine the effect of GOLPH3 on the glycosylation of 
this glycoprotein. Following the RNAi mediated knockdown of the GOLPH3 proteins 
in a human cell line such as a neuroblastoma cells, the glycosylation status of 
RPTPζ/phosphacan will be determined by its reactivity to the monoclonal antibody 
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Cat-315. The antibody has been shown to detect a HNK-1 epitope present on RPTPζ 
in neuroblastoma cell lines (Abbott et al., 2008). Results from this study could offer 
interesting insights into the role of GOLPH3 in regulating the glycosylation of 
RPTPζ/phosphacan which similar to α-dystroglycan is hypoglycoyslated in animal 
models of MEB. These results could serve to further strengthen the link between 
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